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Abstract 
Throughout the human history, the fight against bacterial infections had never stopped 
but the remedies for bacterial infections were often insufficient and for many infectious diseases, 
there was no treatment available. The revolution in antimicrobial infection therapy began with 
the discovery of penicillin by Alexander Fleming in 1928. However, since the first introduction 
of antibiotics, bacteria over time have evolved sophisticated resistant strains against almost all 
the available antibiotics which cause selection pressure on the bacteria to evolve their genetic 
makeup and develop resistance against such agents. Furthermore, bacteria can form surface 
attached multicellular communities known as biofilms. Bacteria residing within biofilms are 
protected by biofilms which renders the bacteria more difficult to eliminate because of the low 
permeability of antibiotics through outer membranes. Combating such resistant bacteria is an 
extremely difficult task if using antibiotics alone. Hence scientific community continuously 
seeks new strategies to overpower these resistant bacteria.   
The focus of the research work presented here is to develop a class of chimera ligands 
that can bind to both pili and LecA protein of Pseudomonas aeruginosa to inhibit both swarming 
motility and biofilm formation. The potential adjuvant agents of these chimera ligands that can 
increase the effectiveness of antibiotics were demonstrated. In addition, the ability of our 
adjuvant molecules to eliminate drug-tolerant bacteria and to reduce persisters, in combination 
with antibiotics was demonstrated.  
The binding property of chimera ligands was demonstrated by competitive fluorescence 
polarization assay (LecA) and by adding a functional group to a ligand that can covalently attach 
to the receptor protein only when the physical ligand-receptor binding takes place (Pili). In 
addition, the effect of externally added pili on the swarming motility of Pseudomonas 
aeruginosa was tested to support the mechanistic study of the pili as the receptor (or one of the 
receptors) that will bind to rhamnolipids and our synthetic agents, and upon binding, causing the 
bacterial activities.  
For quantification of polysaccharides, two efficient detection and quantification methods 
that make use of the negative charges of the alginate polymer and do not involve degradation of 
the targeted polysaccharide were described. Both approaches provide efficient methods for 
monitoring alginate production by mucoid Pseudomonas aeruginosa. 
The effect of a class of synthetic analogs of rhamnolipids at controlling (promoting and 
inhibiting) the biofilm formation activities of a non-rhamnolipid-producing strain – rhlA – 
of Pseudomonas aeruginosa was demonstrated. The bioactive synthetic analogs of rhamnolipids 
promote biofilm formation by rhlA mutant at low concentrations but inhibit the biofilm 
formation at high concentrations. To explore the internal structures formed by the biofilms, the 
wild-type biofilms formed with substantial topography (hills and valleys) when the sample is 
under shaking conditions were observed by confocal microscope. Using this observation as a 
comparison, the effect of synthetic analogs of rhamnolipids on promoting structured (porous) 
biofilm of rhlA mutant, at intermediate concentrations between the low ones that promoted 
biofilm formation and the high ones that inhibited biofilm formation was demonstrated. This 
study suggests a potential chemical signaling approach to control multiple bacterial activities. 
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Chapter 1 Introduction: The Need of Controlling Pathogen Activities of Bacteria 
 
1.1 Bacteria activities – Biofilm, swarming, alginate production, and twitching motilities 
– impact infectious diseases 
1.1.1. Pseudomonas aeruginosa is related to multiple diseases 
Pseudomonas aeruginosa (P. aeruginosa) is a gram-negative, rod-shaped 
opportunistic pathogen associated with a wide range of diseases.1 Common victims of P. 
aeruginosa infections are the patients with weakened immune systems and patients with 
wounds from surgery or burn.2 The P. aeruginosa infection is especially prevalent among 
the victims of cystic fibrosis (CF), which is a genetic disorder that disrupts the normal 
function of epithelial cells where P. aeruginosa colonizes the lung and mutates to an 
alginate overproducing mucoid phenotype.3-4 The alginate-containing matrix of the 
mucoid strain is thought to allow the formation of protected microcolonies and provide 
increased resistance to opsonization, phagocytosis, and destruction by antibiotics.5-6 In 
addition, outer membrane permeability of P. aeruginosa is lower than that of Escherichia 
coli (E. coli).7 P. aeruginosa is intrinsically resistant to many structurally unrelated 
antimicrobial agents because of the low permeability of its outer membrane, the 
constitutive expression of various efflux pumps with wide substrate specificity, and the 
naturally occurring chromosomal AmpC beta-lactamase.8  
 
1.1.2. The clinically relevant mucoid strain of P. aeruginosa 
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Over time P. aeruginosa in the lungs of Cystic Fibrosis (CF) patients converts 
into a mucoid strain which is known to overproduce and secrete the exopolysaccharide 
alginate.3 Alginate production by CF strains is the major source of morbidity for CF 
patients. This is mainly due to the ability of the bacteria to undergo genotypic and 
phenotypic changes from the typical nonmucoid form to a mucoid phenotype.9 The 
relationship between conversion to mucoidy and the establishment of chronic infection is 
still not fully understood. Ever since its discovery in the 70s, the exact causes for this 
conversion to mucoid has been elusive.10 Conflicting opinions have been on the 
contribution from ligands on the airway cells of the patients.11-12 Kharazmi reported that 
exposure of a P. aeruginosa to hydrogen peroxide will cause nonmucoid to mucoid 
conversion.13 Yu and coworkers found that truncation of type IV pilin induces mucoidy in 
certain nonmucoid strain.14 In vitro studies have also indicated that alginate reduces P. 
aeruginosa uptake by rabbit neutrophils, guinea-pig alveolar macrophages, and murine 
peritoneal macrophages, as well as reducing human neutrophil function.15-18  The most 
common mutations responsible for the mucoid conversion are found in mucA, which 
encodes an inner-membrane-associated anti-σ-factor.19-20 MucA normally limits the 
expression of the algD operon, which encodes the enzymes required for alginate 
synthesis.21-23 σ22, which is encoded by algU, regulates stress response and virulence-
associated genes and is involved, directly and indirectly, in the regulation of virulence 
and motility in P. aeruginosa.24-26 This suggests the primary selective advantage of the 
mucA mutations might be activation of the cellular envelope stress response, and the 
overproduction of alginate might be a secondary consequence of the mutations. The 
known or proposed pathogenic roles of alginate can be classified as the following 
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categories: 1) a direct physical barrier against phagocytic cells, 2) alginate production 
may play a role in biofilm-related phenomena, including contribution to adhesion and 
antibiotic resistance owing to the increased impermeability for antibiotics.3, 27-28 Parsek 
and co-workers showed that the biofilm formed by mucoid strain was a thousand-fold 
more resistant than the non-mucoid strain to the action of antibiotic Tobramycin.29 
Hengzhuang and coworkers demonstrated that the treatment of biofilms formed by 
mucoid strains required higher doses and longer treatment times with two antibiotics, 
Colistin and Imipenem, as compared to the biofilms of nonmucoid strain.30 Singh and 
coworkers did explore the use of Esomeprazole molecules to control the biofilms formed 
by mucoid strain.31 In chapter 2, we will introduce a novel alginate quantification method 
that offers better chemoselectivity and easier operations over a conventionally used 
carbazole assay. We also focused on discovering synthetic molecules on inhibiting 
alginate produced by a pathogenic strain of P. aeruginosa (mucoid phenotype) extracted 
from cystic fibrosis patients. 
1.1.3. Bacterial biofilms are a major source of infectious diseases and persistent 
pathogens 
Biofilm is any group of microorganisms in which cells stick to each other on a 
surface.32 P. aeruginosa biofilms are difficult to eliminate because of the low 
permeability of antibiotics through outer membranes of P. aeruginosa.33-34  Parsek and 
his co-workers found that the biofilm formed by mucoid strain was 1000 times more 
resistant than the non-mucoid strain to the action of antibiotics.7 About 80 % of bacterial 
infections in humans are associated with biofilms.35 Bacteria residing inside the biofilms 
are phenotypically different from those within the culture.36 Biofilm formation is 
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commonly considered to occur in the following main stages.(See Figure 1.1) The first 
step of biofilm formation is the reversible attachment of bacteria on the biotic or abiotic 
surfaces which is governed by Van der Waals forces and at this stage bacteria can be 
easily removed from the surface.37 In the second step, bacteria adhere irreversibly onto 
the surface through its pili and flagella.8 In the third step, bacteria start communicating 
with each other through quorum sensing. When a quorum is achieved, bacteria start 
secreting polysaccharides to create a three-dimensional matrix. The fourth step in the 
process is the formation of mature biofilms. Mature biofilm is usually a mushroom-
shaped structure consisting of different phenotypes as we move from cap to root of the 
mushroom. The last step of biofilm formation is a dispersion of mature biofilm. 
Dispersion is an important stage of the biofilm cycle as it allows bacteria to spread and 
colonize new surfaces.38  
The stimulation of biofilm production induced by sub-inhibitory concentrations of 
antibiotics was observed in numerous human pathogens, such as Staphylococcus or 
Pseudomonas species.39 Biofilms can directly challenge the treatment of infectious 
diseases by greatly reducing the antibacterial efficacy of antibiotics.40-41 Within a biofilm, 
bacteria face gradients of physical and chemical parameters, such as nutrients, oxygen, 
pH.40 Thus, those bacteria living within biofilms are in distinct physiological states, 
which increased their capacity to tolerate antibiotics. In addition, the physical barrier 
created by the biofilm structure can hinder the diffusion of antibiotics.29, 33 Biofilm 
formation, induced by sub-inhibitory concentrations of antibiotics targeting ribosomes, 
such as aminoglycosides, phenicols or tetracyclines, was shown to involve cyclic-di-
GMP signaling both in P. aeruginosa and E. coli.42 In P. aeruginosa, biofilm induction 
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requires the presence of an inner membrane protein, coded by the arr gene, containing an 
EAL domain, which is commonly present in enzymes involved in the degradation of the 
cyclic-di-GMP, thus aminoglycosides may modulate the level of this second messenger 
by acting on the inner membrane protein.42 
 
Figure 1.1 The five stages of biofilm development. Stage 1: Planktonic (free-floating) 
bacteria adhere to the biomaterial surface. Stage 2: Cells aggregate, form microcolonies 
and excrete extracellular polymeric substances (EPS), i.e. slime. The attachment becomes 
irreversible. Stage 3: A biofilm is formed. It matures and cells form multi-layered 
clusters. Stage 4: Three-dimensional growth and further maturation of the biofilm, 
providing protection against host defense mechanisms and antibiotics. Stage 5: The 
biofilm reaches a critical mass and disperses planktonic bacteria, ready to colonize other 
surfaces [Citation: Monroe D (2007) Looking for Chinks in the Armor of Bacterial 
Biofilms. PloS Biol 5 (11):e308. Doi: 10.1371/journal.pbio.0050307; Image Credit: D. 
Davies; Copyright: © 2007 Don Monroe. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution and reproduction in any medium, provided the original author and source are 
credited.] 
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1.1.4. Swarming and twitching motilities are multicellular behaviors 
P. aeruginosa exhibits a large variety of translocation movements, including 
swarming, swimming, twitching, gliding, sliding and darting.43 Among those different 
translocation movements, swarming is regarded as a multicellular behavior. Swarming 
bacteria move in multicellular groups and exhibit adaptive resistance to multiple 
antibiotics.44-46  Both biofilm formation and swarming are surface-associated 
multicellular bacterial activities that are inversely regulated.47-48 Swarming is a flagella 
mediated rapid movement of bacteria on a semisolid surface.49-50 Some bacterial species 
like Vibrio parahaemolyticus and Proteus mirabilis swarm on 1.5 to 3% of agar gel while 
other bacteria like E. coli, P. aeruginosa and Bacillus subtilis swarm on 0.5 to 0.8 % agar 
gel.44 Previous studies have suggested that quorum sensing, rhamnolipid production, type 
IV pili, and the flagellum all contribute to swarming.46, 51 Quorum sensing control of 
swarming is thought to be mediated by RhlR, which activates expression of 
the rhlAB genes and these genes encode enzymes required for production of the 
surfactant, rhamnolipid.52-53 While, some strains of P. aeruginosa when inoculated at the 
center of a semisolid surface, grow outward from the point of inoculation to form 
complexly branched tendrils, others simply grow outward from the point of inoculation 
without forming any pattern.54 Figure 1.2 has shown the different type of swarming 
pattern under similar swarming conditions. However, the formation of complex patterns 
on the swarm gels is still being poorly understood. 
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Figure 1.2 Swarm patterns of different P. aeruginosa strains on the semisolid surface 
(0.5% agar). 
 
Henrichsen and coworkers established that the mode of surface-associated 
movement termed “twitching motility” is related to the presence of thin pili on various 
bacterial species.55-56 They also found that strains exhibiting twitching motility form 
“spreading and corroding colonies”.57 It has been shown that type IV pili are required for 
twitching motility.58 Twitching motility is regarded as a result of the extension and 
retraction of pili, which propels the bacteria across a surface.59-60  
1.2. A brief history of antibiotic discovery and their classification 
 
Throughout the human history, the fight against bacterial infections had never 
stopped but the remedies for bacterial infections were often insufficient and for many 
infectious diseases, there was no treatment available.61 Bacterial infections frequently led 
to serious illnesses and caused high mortality rates. The revolution in antimicrobial 
infection therapy began with the discovery of penicillin by Alexander Fleming in 1928.62 
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The development of penicillin for medical use, and its enormously successful application 
during the World War II led to a great interest in searching for other natural antibiotics. 
Use of the whole cell antibacterial activity screening platform developed by Waksman 
directed at a wide variety of fungi and bacteria led to the “golden age” of antibiotic 
discovery.63  
 
There are different ways to classify antibiotics, but the most common 
classification methods are based on their molecular structures and spectrum of activity.64 
Some common classes of antibiotics based on chemical or molecular structures include 
Beta-lactams, Tetracyclines, Quinolones, Aminoglycosides, Macrolides, Sulphonamides, 
Glycopeptides, and Oxazolidinones.65-67 Most of the antibiotics are targeting at a certain 
unique feature of the bacterial structure or their metabolic processes completely different 
or even not presented in mammalian cells.68-70 The common targets of antibiotics are 
presented in Figure 1.3.71  
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Figure 1.3 Sites of antibacterial action and mechanisms of resistance. Antibiotics can be 
classified by their mechanism of action. DHF, dihydrofolic acid; LPS, 
lipopolysaccharide; PABA, para-aminobenzoic acid; THF, tetrahydrofolic acid; TLR4, 
Toll-like receptor 4. [Citation: Brown, D., Antibiotic resistance breakers: can repurposed 
drugs fill the antibiotic discovery void? Nature Reviews Drug Discovery 2015, 14 (12), 
821. doi: 10.1038/nrd4675. Epub 2015 Oct 23. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution and reproduction in any medium, provided the original author and source 
are credited.] 
 
1.3. Antibiotic resistance is a big problem 
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The origin of antibiotics is ancient and antibiotic biosynthetic genes and 
resistance-conferring genes date back to the ancient period.72 Thus, many 
microorganisms have naturally been exposed to these antibiotics over evolutionary 
timescales. It has been proposed that antibiotics have evolved to be global regulators 
within microbial communities, contributing to quorum sensing and microbial 
communication in the natural environment.73-74 At the low concentrations, antibiotics can 
act as signaling molecules that trigger transcription responses important for 
environmental survival.75-76 While the growth of surrounding microorganisms could be 
inhibited at high concentrations of antibiotics are present.77 Since the first introduction of 
antibiotics, bacteria over time have evolved sophisticated resistant strains against almost 
all the available antibiotics which cause selection pressure on the bacteria to evolve their 
genetic makeup and develop resistance against such agents.78-80 Combating such resistant 
bacteria is an extremely difficult task if using antibiotics alone. Hence scientific 
community continuously seeks new strategies to overpower these resistant bacteria.   
 
1.4. Antibiotic adjuvants do not seem to eradicate the problem 
 
An alternative strategy to combat bacterial infections is through using antibiotic 
adjuvants, compounds that enhance the activity of current drugs and can minimize 
resistance.81-83 In general, adjuvants are delivered together with antibiotics and therefore 
are combination drugs which have been used to achieve synergy, cover the microbial 
spectrum, and suppress resistance to enhance and preserve the activity of existing 
drugs.84-87 Such synergistic effects are implying the greater efficacy of the combinations 
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than the sum of the individual components. Antibiotic adjuvants can be divided into two 
general classes based on target profile: Class I adjuvants that work with antibiotics on 
bacterial targets (inactivating enzymes, efflux pump systems, or alternate targets), and 
Class II adjuvants that enhance antibiotic activity in the host.88 The example of beta-
lactamase inhibitors in the clinic over the past decades is proof that the antibiotic 
adjuvants are powerful and important.89  
The molecular basis of antibiotic synergy is poorly understood. However, without 
mechanistic data, machine-learning strategies were applied to predict the efficacy of 
combinations in the antifungal realm and to offer an opportunity to identify new 
antibacterial combinations as well.90 Although there are adjuvant molecules that are 
believed to have a reduced potential to elicit resistance from bacteria, so far do not seem 
to eradicate the problem. 
 
1.5. Our hypothesis: Controlling bacterial activities leads to eliminating antibiotic 
tolerance and new persister formation 
 
It is recognized that antibiotics that kill bacteria can also cause responses that, 
over time, lead to bacterial drug resistance, making the treatment of infectious diseases 
more challenging.8, 91 At sub-lethal concentrations, antibiotics can readily increase the 
population of tolerant bacteria; these tolerant populations require a higher antibiotic 
dosage to kill than typical susceptible bacteria.92 Studies also suggest that drug-tolerant 
bacteria have a higher propensity to evolve into drug-resistant bacteria making antibiotics 
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ineffective, even at a high dosage.93-94 Antibiotics can also enhance a pre-existing 
population of bacteria, called persisters, which are non-growing and thus extremely 
difficult to eradicate using current antibiotics.95-97  
Luk lab has developed a class of molecules that inhibit both swarming motility 
and biofilm formation by P. aeruginosa.98-99 In contrast, at low concentrations, the 
antibiotic tobramycin, a front-line treatment for chronic infections associated with cystic 
fibrosis (CF), increases swarming motility and biofilm formation by P. aeruginosa.100 
This result prompted us to assess our molecules as a potential adjuvant agent to increase 
the effectiveness of tobramycin. Preliminary results show our molecules enable 
tobramycin to kill both planktonic bacteria and tolerant bacteria in a preformed biofilm 
that was promoted by the sub-lethal concentration of tobramycin. Our molecules, in 
combination with antibiotics, also eliminated newly formed persisters in a biofilm that 
are induced upon exposure to antibiotic treatment. This finding is significant, as our 
novel adjuvants will drastically improve the performance of existing antibiotics. Treating 
antibiotic-resistant infections is a major medical concern; which this project can address. 
In the following chapters, we will evaluate the ability of our adjuvant molecules to 
eliminate drug-tolerant bacteria and to reduce persisters, in combination with antibiotics. 
We have established growth conditions that generate tobramycin-tolerant bacteria and 
tobramycin-induced persisters. Using these assays, our preliminary result shows that our 
molecules enable tobramycin to kill tobramycin-tolerant bacteria, as well as to prevent 
the formation of persisters.  
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1.6. A brief introduction of the following chapters 
In Chapter 2, two efficient detection and quantification methods that make use of 
the negative charges of the alginate polymer and do not involve degradation of the 
targeted polysaccharide were described. Both approaches provide efficient methods for 
monitoring alginate production by mucoid Pseudomonas aeruginosa. 
In Chapter 3, the effect of a class of synthetic analogs of rhamnolipids at 
controlling (promoting and inhibiting) the biofilm formation activities of a non-
rhamnolipid-producing strain – rhlA – of Pseudomonas aeruginosa was described. 
In Chapter 4, a class of disaccharide derivatives that can inhibit both swarming 
motility and biofilm formation of Pseudomonas aeruginosa were described. Those 
potential adjuvant agents can increase the effectiveness of antibiotics. In addition, the 
ability of our adjuvant molecules to eliminate drug-tolerant bacteria and to reduce 
persisters, in combination with antibiotics was demonstrated.  
In Chapter 5, the binding property of a fluorophore-derivatized disaccharide to 
LecA protein was demonstrated by fluorescent polarization assay. In addition, the 
binding properties of synthetic molecules to LecA protein were demonstrated by 
competitive fluorescent polarization assay. 
In Chapter 6, the binding property of synthetic ligands to pili protein was 
demonstrated by adding a functional group to a ligand that can covalently attach to the 
receptor protein. In addition, the effect of externally added pili on the swarming motility 
of Pseudomonas aeruginosa was tested to support the mechanistic study of the pili as the 
receptor (or one of the receptors) that will bind to rhamnolipids and our synthetic agents, 
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and upon binding, causing the bacterial activities. Together these results in chapter 5 
suggest that SFβM is a chimeric ligand that binds to two different targets, LecA101-102 and 
pili, and also explains why two distinct processes (biofilm formation and swarming) are 
inhibited by the same molecule. 
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Chapter 2 Quantification of alginate by aggregation induced by calcium ions and 
fluorescent polycations 
 
2.1. Introduction 
2.1.1. Development of alginate quantification methods and its importance 
Quantification of polysaccharides bearing negative charges, such as various 
heparins and alginate, is important for understanding cell signaling for both mammalian 
cells and bacteria.103-105 Various approaches such as colorimetric assays coupled with 
covalent reactions, salt complex forming induced staining, aggregation,106 as well as 
high-performance liquid chromatography-diode array detector methods107 have been 
developed to achieve this goal. Recently, Correa and coworkers have demonstrated the 
successful use of FT-IR spectroscopy to quantify alginate production by several 
Pseudomonas fluorescens strains.108 The most commonly used carbazole assays involve 
heating the polysaccharides with concentrated sulfuric acid followed by an addition of an 
aromatic amine – carbazole. Carbazole-sulfuric acid method was first described by 
Dische108 and further developed by Gurin and Hood109 for the identification and 
estimation of hexoses and pentoses. Later, Bitter described a modification of the 
carbazole method for the analysis of uronic acids, which is the major component of 
alginate.110 Reactivity of several uronic acids and uronic acid-containing 
mucopolysaccharides (MPS) was studied systematically at various temperatures and for 
various heating periods.111 The study revealed that different uronic acids and MPS upon 
heating with sulfuric acid produce products with different absorbance in the carbazole 
assay.111 The acid treatment generates a range of chemical species starting with breaking 
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the glycoside bonds, generating the aldehyde that can react with the amine to form a 
colored imine. Other chemical species from further decomposition such as furic acid 
were reported, giving a chemically poorly defined mixture. A modification of the 
carbazole reaction was obtained, in which the intensity of the color depends not only on 
the structure of individual hexuronic acids but also on specific linkages in 
polyuronides.112 Because of the harsh conditions, and dependence of the reaction on the 
nature of the polysaccharide, carbazole-based assays have been reported to produce false 
positives and inconsistent results for various polysaccharide structures.113 More 
detrimental to the selectivity, both mono- and disaccharides react with the carbazole, 
producing a high level of background noise that requires the purification of targeted 
polysaccharides.  
We are interested in the detection of alginates, polysaccharides with 1-4 linked D-
mannuronic (M) and L-guluronic (G) acid residues that are produced by the opportunistic 
bacterium Pseudomonas aeruginosa. This bacterium often resides in the lungs of patients 
with cystic fibrosis who have mutations in cystic fibrosis transmembrane conductance 
regulator (CFTR) protein, which can cause impaired ion transport.114 In the lungs of 
patients with cystic fibrosis, P. aeruginosa rapidly converts to mucoid P. aeruginosa, a 
phenotype that overproduces alginate. Thus, development of a direct method for the 
detection of alginate without purification from the culture of mucoid phenotype is greatly 
desired for the screening of chemical agents that can inhibit the production of alginate by 
the pathogenic strain of P. aeruginosa. 
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2.1.2. The aim of the chapter 
 
In this chapter, we report two new approaches to detect the production of alginate. 
In the first method, calcium ion is used to aggregate the alginate in situ without purifying 
the alginate from the culture medium; the aggregates were hydrogel-like and quantified 
by using the conventional crystal violet dye assay. In the second method, alginate 
aggregation was induced by multivalent binding between a fluorescently-labeled 
polycation and alginate. This approach (labeling the polycation) provides a sensitivity 
comparable to that of the carbazole assay, but without the need for chemical reactions 
and multiple steps of operations. we will describe two efficient detection and 
quantification methods that make use of the negative charges of the alginate polymer and 
do not involve degradation of the targeted polysaccharide. The first method utilizes 
calcium ions to induce hydrogel-like aggregate with alginate polymer; the aggregates can 
be readily quantified by staining with a crystal violet dye. This method does not require 
the purification of alginate from the culture medium and can measure a large amount of 
alginate that is produced by a mucoid Pseudomonas aeruginosa culture. The second 
method employs polycations tethering a fluorescent dye to form suspension aggregates 
with the alginate polyanion. Encasing the fluorescent dye in the aggregates provide an 
increased scattering intensity with a sensitivity comparable to the conventional carbazole 
assay. Both approaches provide efficient methods for monitoring the alginate production 
by mucoid. 
2.2. Results and discussion 
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2.2.1. Design of alginate quantification methods by aggregation induced by calcium ions 
and fluorescent polycations 
P. aeruginosa is an opportunistic Gram-negative bacterium that can undergo 
phenotypic changes to convert from the wild-type to a mucoid phenotype in the lungs of 
immunocompromised individuals (e.g. with fibrosis patients).9, 115-116 This mucoid strain 
is characterized by the overproduction of alginate polysaccharides, which are copolymers 
of 1-4 linked D-mannuronic and L-guluronic acid residues.117 The adhesion of mucoid 
alginate to the lung of a patient is a major virulence factor that causes a series of 
problems including hosting dormant bacteria, reducing the effectiveness of antibiotics, 
and difficulty in breathing.118 We are interested in developing methods for efficient 
detection of alginate production by mucoid P. aeruginosa. Such methods are useful for 
evaluating chemical agents that can inhibit alginate production by the mucoid strain.   
The conventional carbazole assay does not take advantages or make use of the 
existence of negative charges on the alginate polymer. Here, we explore the multiple 
carboxylate groups in the alginate to enable aggregation and detection by using two 
different approaches. First, we use calcium ion to form aggregates with alginates, 
followed by crystal violet staining of the aggregate as a quantification means. Second, we 
explore the aggregation induced by the multivalent binding between a polycation, 
polyallylamine (PAA), and alginate in aqueous solutions (Figure 2.1). To increase the 
sensitivity of this method, we also covalently modified PAA with fluorescein 
isothiocyanate (FITC), a fluorescent fluorophore. Polyallylamine (PAA) tethered with 
FITC has been used in many applications, including the photophysical study of 
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fluorescent core nanoparticles fabricated by the layer-by-layer assembly,119 probes for 
TNT detection based on FRET120 and colloidal DNA carriers.121 
 
 
 
 
 
 
 
 
 
Figure 2.1 Schematic representation of aggregate formation between (A). Alginate and 
calcium ions, (B). Polyallylamine (PAA)-FITC and alginate.  
 Calcium and other divalent metal ions have long been recognized to form an 
aggregate with alginate polymers due to the chelation of the carboxylate groups of the 
polymer with calcium.122 The direct detection of these aggregates, however, has not been 
explored. Here, we first examine the effect of calcium ion present in growth medium 
alone for bacterial culture to evaluate the background noise, if any, from calcium ion in 
the LB broth. Figure 3 shows that, after treatments with Ca2+, sodium alginate and 
mucoid P. aeruginosa grown in LB broth media form aggregates, while LB broth media 
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itself and wild-type P. aeruginosa PAO1 grown in LB broth media do not show any 
aggregate after Ca2+ treatment (Figure 2.2). This result suggests that calcium ion does not 
cause any aggregation in LB broth alone but causes aggregation for both purchased 
sodium alginate and the alginate produced by mucoid P. aeruginosa.  
 Upon adding calcium chloride, the mucoid P. aeruginosa culture exhibits the 
formation of large aggregates. After centrifugation of this culture solution, we observed 
cell pellets at the bottom of the falcon tube. In the solution above the cell pellets, large 
hydrogel-like calcium alginates are observed. The calcium alginate was recollected by 
pouring out the supernatant along with the hydrogel-like aggregate; the cell pellet was 
left behind and discarded. 
 
Figure 2.2 Pictures of (A) 2 mL of 6 mM CaCl2 mixed with 200 µL of 5 mg/mL of 
sodium alginate; (B) 500 µL of 60 mM CaCl2 mixed with 5 mL of LB broth media; (C) 
500 µL of 60 mM CaCl2 mixed with 5 mL mucoid P. aeruginosa (OD=0.7) grown in LB 
broth media; and (D) 500 µL of 60 mM CaCl2 mixed with 5 mL wild-type P. aeruginosa 
PAO1 (OD=0.7) grown in LB broth media. Before adding CaCl2, the solution was 
centrifuged; and the bacteria pellets were removed.  
A B C D 
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 We quantified the resulting aggregates by staining them with a crystal violet dye – 
a common staining agent.123 To establish the concentration dependence, we studied the 
optical density of aggregates formed between calcium and commercially available 
sodium alginate with a series of concentrations from 0.1 mg/mL to 2 mg/mL. A linear 
correlation between 0.2 mg/mL to 2 mg/mL are readily obtained (Figure 2.3). However, 
the signal is rather weak when the concentration of alginate is lower than 0.2 mg/mL 
(corresponding to an OD value of 0.04 for 0.2 mg/mL of alginate).   
 
 
Figure 2.3 Optical density at 600 nm of calcium alginate by crystal violet dye staining 
assay  
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2.2.2. Quantification of by alginate produced by mucoid P. aeruginosa  
 
 Next, using this linear relationship, we quantified alginate produced by mucoid P. 
aeruginosa over the span of 24 h culture. In this study, we used a mucoid phenotype 
(PA2192) isolated from CF patients. Goldberg and coworkers revealed the differences 
between proteins expressed by CF isolates of P. aeruginosa that have phenotypes 
associated with the initial versus chronic infection process.124 Figure 2.4.A shows the 
growth curve of mucoid P. aeruginosa in 24 h, Figure 2.4.B shows the corresponding 
alginate production in mg/mL determined by using crystal violates dye staining assay. 
Our result showed that mucoid P. aeruginosa did not produce any noticeable amount of 
alginate in the first 2 hours, but measurable amount of alginate was observed after 3 
hours. This result is consistent with the notion that significant alginate production by 
mucoid P. aeruginosa starts in the exponential growth period and reaches a plateau after 7 
hours when the bacterial growth slows down. 
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Figure 2.4 Plot of  (A) the mucoid P. aeruginosa growth curve, and (B) the optical 
density of Ca2+ induced aggregation of mucoid alginate by using crystal violate dye 
staining assay, versus time of culture. The bacterial culture was grown in LB broth media 
shook at 250 rpm.  
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 2 4 6 8 10 12 14 16 18 20 22 24O
D
6
0
0
 o
f 
M
u
c 
PA
 c
u
lt
u
re
 
Time/h
0
0.5
1
1.5
2
0 2 4 6 8 10 12 14 16 18 20 22 24
A
lg
in
at
e 
p
ro
d
u
ce
d
 b
y 
M
u
c 
PA
 (
m
g
/m
L)
 
Time/h
A. 
B. 
 24 
 
2.2.3. Comparison of different alginate quantification methods 
 Comparing to the carbazole assay, the calcium aggregation-CV staining method 
can directly measure 0.05 mg/mL (or more) alginates without dilution and without 
purification, which is well-suited for monitoring the alginate production by mucoid P. 
aeruginosa. More importantly, the calcium aggregation method does not have a 
background signal for pure LB broth medium, for carbazole assays, however, a 
background signal of the optical density of ~0.12 for pure LB broth was observed. This 
value is comparable to the signal from 0.04 mg/mL of sodium alginate in water (Figure 
2.5 and Figure 2.6). However, the sensitivity of measuring the optical density of calcium-
alginate aggregation (not staining method) is limited to about 0.2 mg/mL of alginate in 
solution.  
 
Figure 2.5 Optical density at 540 nm of sodium alginate aqueous solution (0~1.0 mg/mL) 
by carbazole assay 
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Figure 2.6 Optical density at 540 nm of 0 mg/mL, 0.02 mg/mL, 0.04 mg/mL sodium 
alginate aqueous solution and LB broth media by carbazole assay 
 
 Considering this low sensitivity, we explored the use of a polycation to aggregate 
alginate. Polycations readily form aggregates with polyanions through multivalent 
binding. This aggregation effect is used in various applications, including layer-by-layer 
deposition of polyelectrolytes125 and medical and pharmaceutical applications like self-
assembled shells for drug delivery.126 By mixing 2 mL of poly allylamine (0.5 mg/mL) 
and 200 µL of sodium alginate (0.5 mg/mL), a cloudy and stable suspension solution was 
obtained (Figure 2.7), rather than a hydrogel-like aggregate. Because the suspension is 
stable, we measured the optical density directly to correlate to the amount of alginate 
present in the solution. Sodium alginate in solution forms aggregates by mixing with a 
CaCl2 or PAA solution. However, our method shows that using a solution of CaCl2 or 
PAA, the optical density value was less than 0.16 when the sodium alginate concentration 
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is 0.50 mg/mL (Figure 2.5), whereas, for carbazole assay, the optical density is around 1.0 
for the same sodium alginate concentration.  Thus, the sensitivity of these two methods is 
still low, and not comparable to carbazole assay.  
 
 
 
 
 
Figure 2.7 Pictures of the solution of 2 mL of 0.5 mg/mL of PAA (A) mixed with 200 µL 
of 5 mg/mL of sodium alginate to form aggregates (B).  
To improve the sensitivity of an aggregation assay, we grafted a fluorophore onto 
the polycation to explore an increase in the optical density signal. As the intensity of the 
light scattering depends on the induced dipoles in the particles – a phenomenon less 
explored for applications, we believe that introducing polarizable groups into the 
aggregates will increase the polarizability of the particle, and thus may increase the signal 
intensity. Furthermore, as the fluorophores are confined in the aggregates, a coherent 
scattering is possible, which further increases the scattering. Mixing alginate with 
fluorescent polycations resulted in a similarly stable suspension of aggregates (inset of 
Figure 2.8). Measuring the UV-Vis spectra of different concentrations of sodium alginate 
in the presence of 0.5 mg/mL PAA-FITC showed a band at 495 nm, which decreased as 
the concentrations of added sodium alginate were increased. Interestingly, the baseline of 
A B 
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the UV intensity from 250 to about 850 nm increased significantly with the concentration 
of added sodium alginate. This result is consistent with increased light scattering due to 
the fluorescent aggregates. To measure the light scattering, we plotted the optical density 
at 405 nm (OD405) of the solution mixtures with different sodium alginate concentrations 
(0.01~0.50 mg/mL). A linear relation between the optical density and the alginate 
concentration was obtained (Figure 2.9). Comparing to the optical density obtained from 
polyallylamine (without fluorescent labeling) and alginate, this result indicates that 
fluorescent aggregates increase the intensity of optical density measurement. Thus, this 
fluorescent polycation enables a more sensitive method for detecting targeted molecules 
through aggregation. 
 
 
Figure 2.8 UV-Vis Spectra of different concentrations of sodium alginate in the presence 
of 0.05 mg/mL PAA-FITC. The pictures of the solution of 2 mL 0.5 mg/mL of PAA-
FITC (A) and the solution of 2 mL 0.5 mg/mL of PAA-FITC mixed with 200 µL of 5 
mg/mL of sodium alginate to form aggregates (B) are also shown. 
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Figure 2.9 includes the signals for optical absorption of the carbazole dye reacted 
with the decomposed alginate, optical density of aggregation with PAA-FITC, PAA, and 
calcium chloride as a function of the concentration of sodium alginate. At relatively high 
concentration, 0.5 mg/mL, aggregation with CaCl2 and PAA showed an optical signal less 
than 0.2, whereas aggregation with PAA-FITC and carbazole assay showed optical 
signals above 0.8. These results indicate that aggregation with PAA-FITC and carbazole 
assay offer a larger signal range than aggregation with CaCl2 or PAA. This result also 
indicated that aggregation using PAA-FITC has a comparable sensitivity to the carbazole 
assay, the conventional method for detecting alginate. However, aggregation with PAA-
FITC does not require multiple steps of covalent reactions. This simplification increases 
the ease of the operation and the reliability of the results, as the reaction yields of the 
covalent reactions become irrelevant.   
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Figure 2.9 Plot of optical density (OD405) of sodium alginate aqueous solution treated 
with 6 mM of CaCl2, 0.5 mg/mL of PAA, or 0.5 mg/mL of PAA-FITC solution; and the 
optical absorption (at 540 nm) of carbazole dye reacted with decomposed alginate. 
2.3. Conclusion 
 
To conclude, we demonstrated two efficient methods for detecting and 
quantifying alginate polymer in a solution. The calcium aggregation-staining assay stains 
directly the calcium-alginate aggregates formed in a bacterial culture without purification 
and provides a one-step detection/quantification method. This assay has a dynamic range 
(0.05 mg/mL and up) that is suitable for monitoring and quantifying the alginate 
production by mucoid P. aeruginosa directly from an LB broth culture over 24 h. Using 
polycations tethered with fluorescent dyes, we obtained the sensitivity that is similar to 
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carbazole assay.  To conclude, the calcium aggregation-staining method does not require 
the purification and can be used directly for detecting the alginate produced by a mucoid 
P. aeruginosa culture, whereas aggregation by fluorescently labeled polycations provides 
similar sensitivity to conventional carbazole assays; and both methods do not require 
covalent reactions and multiple steps of operations.  
 
2.4. Materials and methods 
 
2.4.1. Bacterial strains and growth media    
 
Wild-type P. aeruginosa, PAO1 were obtained from Dr. Guirong Wang (Upstate 
Medical University). Mucoid P. aeruginosa strain PA2192 was isolated from CF patients 
by Dr. Goldberg at Emory University.27, 28 All the bacterial strains were grown in Luria-
Bertani (LB) medium containing 10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl at 
37 °C.  
 
2.4.2. Synthesis of PAA-FITC29 
 
Fluorescein isothiocyanate (FITC) was dissolved in dimethyl sulfoxide (final 
concentration of 1 mg/mL) and protected from light by wrapping the tube in aluminum 
foil. The FITC solution (40 µL) was then added to each milliliter of a 2 mg/mL 
polyallylamine (PAA, average Mw ~17,500) solution of pH ≈ 10 so that the FITC to -
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NH2 monomer ratio was 1:50. The mixture was gently stirred and allowed to react at 4 °C 
overnight. The PAA-FITC product was purified by adding acetone to the reaction mixture 
resulting in the precipitation of the product forming a cloudy solution. After centrifuged 
at 8.5 x 103 rpm for 10 min, a reddish-brown precipitate was observed, and the solution 
was discarded. The precipitates were further washed with acetone and dried overnight by 
vacuum. By comparing the neat UV absorption of FITC in 1:1 MeOH/H2O solution and 
PAA-FITC product in 1:1 MeOH/H2O solution, we have confirmed there is no 
observable unreacted FITC in either the precipitate product or in the solution, or in the 
reaction mixture before precipitation. The reaction is quantitative, and the ratio of FITC 
to the monomers of PAA is 1 to 50. Thus, the degree of labeling (DOA) is 3.76 FITC per 
polymer of PAA, which contains an average of 188 monomers. 
 
 
Figure 2.10 Synthesis of PAA-FITC 
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2.4.3. Quantification of alginate by crystal violet dyed glycolipid assay 
 
            A solution of 500 µL CaCl2 (60 mM) was added to 5 mL of neutral (pH 7.0) 
aqueous solution containing known concentrations of sodium alginate. A hydrogel-like 
suspending aggregate was observed. The mixture was centrifuged at 5600 rpm for 5 min.  
The supernatant was removed by discarding the solution while using a glass rod to 
prevent alginate aggregate from falling out. The alginate aggregate was then rinsed 3 
times with deionized water (18 mΩ) to obtain a wet alginate. The alginate aggregate was 
soaked in 500 µL of 0.3 % crystal violet (CV) dye aqueous solution for 20 min.  The CV 
dye solution was discarded, and the alginate was rinsed 3 times with deionized water. The 
absorbed CV dye was then extracted from the aggregate by 5 mL acetic acid and gently 
shaking. The optical density of the dye solution is measured by using 100 µL with a 96-
well plate on a Biotek ELx800 Absorbance Microplate Reader at a wavelength of 600 
nm.  
 
2.4.4. Quantification of alginate by direct optical density measurement assay 
 
          Stock solutions of 60 mM CaCl2, 0.5 mg/mL PAA and 0.5 mg/mL PAA-FITC 
solution are prepared. Stock solutions (100 µL of CaCl2, PAA or PAA-FITC) were mixed 
with 1 mL of sodium alginate aqueous solution with known concentrations by using a 
vortex mixer. The optical density of the solutions was measured by using 100 µL in a 96-
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well plate on a Biotek ELx800 Absorbance Microplate Reader at a wavelength of 600 
nm.  
 
2.4.5. Carbazole assay 
 
Carbazole assay was performed as described by A. M. Chakrabarty and 
coworkers, with slight modifications.25 Briefly, a borate stock solution was prepared by 
diluting 24.7 g of H3BO3 in 45 mL of 4 M KOH to a total of 100 mL using sterile water. 
Before every use, a borate working solution was prepared by mixing 1 part of the borate 
stock solution with 40 parts of 98% H2SO4, and a 0.1 wt % carbazole solution was 
prepared in ethanol. Before doing the assay, the borate working solution was put in an 
ice-water bath for 10 min. A 70 µL of sodium alginate sample with known concentrations 
(0.01 to 1.00 mg/mL) was added onto the ice-cold borate working solution. Two layers of 
the solution were observed; the solution (sample mixture) was for about 4 sec by using a 
vortex and put back to the ice-water bath. A carbazole solution (20 µL) was added onto 
the sample mixture and warmed at 55 °C for 30 min. The absorbance at 530nm was 
measured. The standard curve was derived by plotting absorbance against the 
concentration of sodium alginate ranging from 0.01 to 1.00 mg/mL.  
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Chapter 3 Synthetic Analogs of Rhamnolipids Modulate Structured Biofilms 
Formed by Rhamnolipid-nonproducing Mutant of Pseudomonas aeruginosa 
 
3.1. Introduction 
3.1.1. The importance of rhamnolipids and its analogs on biofilm structure 
 Bacterial biofilm is the source of infectious diseases in many contexts, including 
in human hosts with compromised immune systems, and on a wide variety of surfaces in 
contact with aqueous solutions.127-130 These bacterial biofilms consist of sophisticated 
internal structures including pore and channels, mushroom and pillar-like structures,131-132 
heterogeneous distribution of secreted chemicals and bacteria strains.133 The biology of 
forming such structured biofilms is complex, and not well understood for a wide range of 
microbes. For Pseudomonas aeruginosa, a class of molecules called rhamnolipids are 
secreted; the presence of these secreted molecules are critical for forming structured 
biofilms with pore and channels.134-137 When the biofilms age, rhamnolipids are also 
needed for dispersion of bacteria from the biofilm.138-140  In addition, this class of 
molecules, rhamnolipids, is also required for the swarming motility of P. aeruginosa on 
an aqueous soft gel surface.46, 141-142 Interestingly, while biologists have established how 
rhamnolipids are produced 143-145 and regulated146-147 in the bacteria and have identified 
many, if not all, of the bio-functions of rhamnolipids, we still do not know the 
mechanism of how rhamnolipids build such structured biofilm or enable and facilitate the 
swarming motility of the bacteria. One of the challenges is that rhamnolipids are 
surfactants, and thus, it is not clear if the mechanism of their functions is just physical – 
by reducing the surface tension; or is biological – by having one or more specific 
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receptors, the binding of which triggers a series of chemical signaling events that control 
these activities; or whether both physical and biological mechanisms are involved.141-142 
 Recently, we have demonstrated that some synthetic molecules with a polar head 
group and an aliphatic chain can reinitiate and promote the swarming activities of rhlA – 
a mutant of P. aeruginosa that does not produce rhamnolipids, and thus does not 
swarm.148-149 While these synthetic molecules are also surfactants, the potent members 
inhibit the swarming motility of the wild-type Pseudomonas aeruginosa (PAO1). This 
result, along with other findings, suggests that the mechanism of rhamnolipids and these 
synthetic analogs are unlikely to be physical or a surfactant effect because our molecules 
can also reduce the surface tension, and would offer the same physical mechanism 
argument. The activities of swarming modulation (promotion and inhibition) are 
extremely sensitive to the molecular details while all molecules resemble surfactant 
structure and show surface activities. In addition, synthetic molecules with intermediate 
potency exhibited oscillation in their bioactivities (promoting and inhibiting swarming 
motility) as a function of concentration in the soft gel. This oscillation of bioactivities is a 
strong indication of cell signaling events responding to an external stimulus.150-151 
Furthermore, novel biological phenomena were observed. Synthetic molecules with 
intermediate potency at controlling swarming motility induce tendril formation in the 
swarming pattern152 suggesting the formation of two opposite phenotypes – 
hyperswarming and lazy-swarming – while abandoning the original phenotype.148 Thus, 
this class of synthetic molecules represents a class of chemical signals.148-149 While these 
findings have focused on the influences on swarming motilities, in this work, we 
demonstrate that synthetic analogs of rhamnolipids, at different concentrations, promote 
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biofilm formation, help build structured biofilm, as well as inhibit the biofilm formation 
by a mutant of Pseudomonas aeruginosa – rhlA – that does not produce rhamnolipids and 
forms non-structured and thin biofilms.  
3.1.2. The aim of the chapter 
In this chapter, we explore the effect of a class of synthetic analogs of 
rhamnolipids at controlling (promoting and inhibiting) the biofilm formation activities of 
a non-rhamnolipid-producing strain – rhlA – of P. aeruginosa. This class of rhamnolipid 
analogs is known to modulate the swarming motilities of wild-type PAO1 and rhlA 
mutant, but its effect on biofilm formation of the rhlA mutant is unknown. We show that 
small structural details of these molecules are important for the bioactivities, but do not 
affect the general physical properties of the molecules. The bioactive synthetic analogs of 
rhamnolipids promote biofilm formation by rhlA mutant at low concentrations but inhibit 
the biofilm formation at high concentrations. To explore the internal structures formed by 
the biofilms, we first demonstrate that wild-type biofilms are formed with substantial 
topography (hills and valleys) when the sample is under shaking conditions. Using this 
observation as a comparison, we found that synthetic analogs of rhamnolipids promoted 
structured (porous) biofilm of rhlA mutant, at intermediate concentrations between the 
low ones that promoted biofilm formation and the high ones that inhibited biofilm 
formation. This study suggests a potential chemical signaling approach to control 
multiple bacterial activities.  
3.2. Results and discussion 
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3.2.1. Structural considerations for rhamnolipids analogs 
 We choose six disaccharide-hydrocarbons to explore their activities in controlling 
the biofilm formation by rhlA mutant (Figure 3.1). These synthetic molecules consist of a 
disaccharide moiety tethered with various single aliphatic chains. We note that while 
these small molecules do not bear significant structural similarity to rhamnolipids, 
depending on the specific structures, they can mimic or dominate the activities of 
rhamnolipids at controlling swarming motilities.148-149 Two of these molecules, saturated 
farnesyl-β-maltoside (SFβM) and saturated farnesyl-β-cellobioside (SFβC), are strong 
inhibitors of the swarming motility of PAO1 strain; and do not initiate swarming by rhlA 
mutant, and are strong inhibitors of biofilm formation by PAO1 strain.148 Two of them, 
dodecyl-β-maltoside (DβM) and benzophenonedecyl-β-maltoside (BPDeβM), promote 
swarming of rhlA mutant and can cause tendril formation at specific concentrations in the 
soft gel; they are also an intermediate inhibitor of biofilm formation relative to the 
saturated farnesol derivatives.149 Here, we explore two more new structures, with the 
introduction of an ether linkage in the two different positions in eleven-carbon aliphatic 
chains that are tethered with a cellobioside, C6OC5βC, and C3OC8βC.  These two 
structures allow us to explore the effect of other functional groups (ether) rather than just 
hydrocarbons at controlling the activities of P. aeruginosa.   
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Figure 3.1 Structures of rhamnolipids and their analogs with disaccharide maltose (M) or 
cellobiose (C) tethered with different aliphatic chains.  
3.2.2. Active synthetic analogs of rhamnolipids stimulate and then inhibit biofilm 
formation by rhlA mutants 
We first use the traditional crystal violet staining assay to characterize the total amount of 
biofilm formed by the rhlA mutant in the presence of different concentrations of the six 
disaccharide hydrocarbons. Interestingly, for DβM, BPDeβM, SFβM, and SFβC, 
promotion of the biofilm formed by rhlA mutants is observed as the concentration is 
increased from 20 µM to 170 µM, in 24 h under non-shaking condition. The inhibition of 
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biofilm formation is observed, most noticeably for SFβM and SFβC, when the 
concentration is further increased to 340 µM (Figure 3.2A).  For C6OC5βC and C3OC8βC, 
there is no noticeable change in the amount of biofilm formed over the entire range of 
concentrations studied, in comparison to the control, to which there are no agents added.   
To examine the effect of our rhamnolipids-analogs at reducing the count of 
bacteria from the biofilm as a consequence of biofilm inhibition, we dried the 24-h old 
biofilm of rhlA mutant, and reintroduced fresh media, and measured the optical density 
of the media that contained bacteria from the biofilm. At relatively low concentrations 
(20 µM and 40 µM), DβM, BPDeβM, SFβM, and SFβC have no significant effect on the 
bacteria in the biofilm, while at 340 µM, the number of bacteria from the biofilm is 
reduced almost by half. For C6OC5βC and C3OC8βC, there is no noticeable change in the 
number of bacteria that remained in the biofilm (Figure 3.2B). These results are 
consistent with the corresponding amount of biofilm inhibited (Figure 3.2A).   
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Figure 3.2 The percentages of biofilm that remained (A) were obtained by comparing 
biofilm content treated with an agent to the control (without agents). The percentages of 
bacteria from a 24-h old rhlA mutant biofilm (B) were obtained by comparing the OD600 
of LB media in contact with rhlA biofilm without our agents (control) to that with our 
agents under identical conditions. Added agents from left to right are I. DβM, II. SFβM, 
III. SFβC, IV. BPDeβM, V. C6OC5Βc, VI. C3OC8βC. Error bar is the standard error of 
the mean from six replicates. 
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For inhibiting the biofilm formation, the effective concentrations for the rhlA 
mutant (340 µM), are considerably higher than for wild-type PAO1. Considering this 
high concentration, we examined the growth of the rhlA mutant in the presence of the six 
molecules. At both 20 µM and 340 µM (Figure 3.3), these agents did not exhibit any 
significant influence on the growth of rhlA mutant of P. aeruginosa in shaking culture 
media. This result indicates that the mechanism of biofilm inhibition is not due to any 
bactericidal effect, but rather likely due to the interference of a ligand-receptor binding 
that triggers signaling events.   
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A. 
 
B. 
 
Figure 3.3 rhlA mutant of P. aeruginosa growth–response curve with and without 20 
µM(A) or 340 µM(B) rhamnolipids analogs. Error bar is the standard error of the mean 
from six replicates. 
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Because rhlA mutant, which does not produce rhamnolipids, forms a nonporous 
biofilm, rhamnolipids are implicated in the formation of porous biofilm.134 However, the 
exact mechanism of how rhamnolipids help create such a porous biofilm is not clear yet. 
We have previously shown that externally added rhamnolipids had only a mild effect on 
inhibiting biofilm formation of PAO1 strain.149 Together with the fact that rhlA mutant 
form biofilms slower and form thinner biofilms than a PAO1 strain, rhamnolipids are 
required for efficient formation of full biofilms. Thus, we believe that, in a biofilm 
growth experiment, a significant amount of synthetic analogs of rhamnolipids are first 
used to facilitate efficient formation of biofilm; only when the full biofilm is formed, 
additionally added rhamnolipids-analogs may then start to inhibit the formation of 
biofilm. Thus, this strong requirement of rhamnolipids or rhamnolipid-analogs for 
biofilm formation caused a high concentration requirement for the rhamnolipid-analogs 
to exhibit biofilm inhibition activities for rhlA mutants. The mechanism of how 
rhamnolipids or its analogs are facilitating the biofilm formation is still not clear. As 
these molecules are likely causing cell signaling events, we believe that the presence of 
these ligands is changing the expression level of their receptors.  
We have previously demonstrated that synthetic agents that are active for 
controlling swarming motility may or may not be active for inhibiting biofilm formation. 
For example, saturated farnesol tethered with tetra(ethylene glycol) inhibits swarming but 
not biofilm formation, whereas saturated farnesol tethered with disaccharides strongly 
inhibits both swarming and biofilm formation.149 Furthermore, swarming motilities is 
sensitive to the agents’ concentrations, in that oscillation in swarming activities is 
exhibited as the concentration increases. For these reasons, we carried out a detailed 
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concentration study on the effect of ether-linked disaccharides (C6OC5βC and C3OC8βC) 
on the swarming motility of PAO1 and rhlA mutants. For controls, we used DβM with 
more expanded concentration ranges than that previously studied.148-149 Figure 4 shows 
that while DβM activated swarming of rhlA and further caused tendril formation in the 
swarming pattern, C6OC5βC did not show a noticeable effect for influencing the 
swarming motilities of rhlA mutant. For PAO1, C6OC5βC also did not show any 
noticeable effect on swarming, but expanded concentrations of DβM indicated slight 
promotion of swarming at about 50 µM and caused tendril formation at 85 µM or higher 
(Figure 3.4). Wild-type P. aeruginosa, PAO1, does not form tendrils on its own. 
Together with the sensitivity to the chemical agents’ structural details, this chemically 
induced tendril formation suggests a ligand-receptor binding event for DβM. We note 
that C3OC8βC is also not active (Figure 3.5). Thus, ether-linked disaccharides are not 
active for controlling either swarming or biofilm formation. These results suggest that the 
structures of the aliphatic chains play a critical role in controlling the bioactivities of the 
molecules.  
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A 
 
B 
 
Figure 3.4 Swarming patterns (A) and the plots of swarming areas of rhlA and PAO1 
strains on the soft gel (0.5 wt% agar) containing different concentrations of DβM and 
C6OC5βC. Controls contain no added synthetic agents. The concentrations are shown 
above the swarming images. Images were taken 24 h after inoculation of bacteria at the 
center of the plate.  
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Figure 3.5 Swarming of PAO1 and rhlA on the soft gel (0.5% agar) with the presence of 
different concentrations of (A) C6OC5βC and (B) C3OC8βC. Compounds do not promote 
swarming of rhlA or promote tendril formation in PAO1. Bacteria were inoculated at the 
center of the semisolid gels (~0.5 % agar). Pictures were taken 24 h after inoculation with 
bacteria.   
 
3.2.3. Shaking produces structured biofilms by PAO1 strain 
To explore whether our synthetic analogs can produce structured biofilms, in 
addition to promoting biofilm formation, we first explore conditions that will give 
structured and less-structured biofilms. It is known that flow of media can enhance the 
production of structured biofilms with channels, pores, and in general, with a high degree 
of topography.131, 133, 137 Tolker-Nielsen and coworkers have reported that in under flow 
conditions, biofilms were formed with channels and pores.131, 133 Unfortunately, for 
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synthetic analogs, the number of agents we obtain from organic synthesis is quite limited 
in comparison to the amount needed for continuous flowing of agent-contained media 
that last for hours to days. For this reason, we seek a different and new condition that 
would allow us to explore the effect of our agents on the structure of the biofilm formed 
by the rhlA mutant. To create a dynamic condition of the media, but without flow, we 
explored shaking of the 96-well plate, in which biofilm is formed, to examine the 
structures (pores and channels) of biofilm with and without such shaking agitation.   
We first tagged PAO1 and rhlA strains with plasmid pSMC2 that constitutively 
expresses the green fluorescent protein,153 and then examined the biofilms formed by 
these bacteria with and without shaking.  Figure 3.6 shows that PAO1 formed a flat and 
thick bed of biofilm in the non-shaking condition. Shaking the plates with 100 rpm, 
PAO1 biofilm exhibited distinct features that resembled structured biofilm, including 
topography of hill and valley-like structures in the confocal fluorescent signals, instead of 
a plain flat biofilm. However, rhlA mutant formed flat and thinner biofilm with and 
without shaking. This result indicates that shaking at 100 rpm produce a highly structured 
biofilm by PAO1. For the rhlA mutant, this strain produced significantly less biofilm than 
PAO1 strains, and the biomass with and without shaking is at a similar level. The 
mechanism, whether physical or biological in nature, is unknown for how shaking 
induces the formation of such structured biofilm of P. aeruginosa. Considering the 
drastic structural difference in the PAO1 biofilm produced with and without shaking, we 
used these two kinds of biofilm as standards to compare and evaluate the degree of 
structural features of biofilms formed by the rhlA mutant that is stimulated by the 
presence of our synthetic analogs.  
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Figure 3.6 The effect of shaking (non-shaking and 100 rpm) on biofilm formation by the 
rhlA mutant of P. aeruginosa in 24h. Representative confocal laser scan microscopy 
(CLSM) images (A) of biofilm formed by rhlA- EGFP mutant (plasmid pSMC2 that 
expresses green fluorescent protein). Scale bar = 76 µm. 
3.2.4. Synthetic analogs of rhamnolipids induce structured biofilm formed by rhlA mutant  
Next, we examined the influence of synthetic analogs of rhamnolipids on biofilm 
structures of rhlA-EGFP strain formed under non-shaking conditions by using confocal 
fluorescence. At 24 h, there is visibly more fluorescence signal for biofilm formed by the 
rhlA-EGFP strain which was treated with 20 µM of all four agents, DβM, BPDeβM, 
SFβM, and SFβC, than biofilm formed without any added agents. Among these agent-
treated biofilms, BPDeβM caused the most biofilms. When we examined the same 
biofilms but treated with 340 µM instead of 20 µM of the four agents, each biofilm 
sample formed by rhlA-EGFP strain showed less fluorescent signal than the control 
biofilm that had no added agents (Figure 3.7). These results suggest that at 340 µM, all 
four agents, DβM, BPDeβM, SFβM, and SFβC, are inhibiting the biofilm formation. To 
confirm these results – promotion at 20 µM and inhibition at 340 µM – we examined the 
biofilm formed by the rhlA-EGFP strain with the same agent treatments (20 and 340 µM) 
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after 48 hours of culture. Overall, more biofilm was observed for all samples. For 
BPDeβM, SFβM, and SFβC, more biofilms were observed for samples containing 20 µM 
of agents than the control sample without agent treatment; however, significantly less 
biofilm was observed for samples containing 340 µM of agent than the control. These 
results suggest that BPDeβM, SFβM, and SFβC inhibited biofilm at 340 µM. The agent 
DβM did show a slight promotion of biofilm at 20 µM, but a comparable amount of 
biofilms were observed at 340 µM. To quantify the amount of biomass of the biofilm, 
software COMSTAT was used. According to the COMSTAT-based quantification of 
biomass, 10 % ~ 60 % biofilm promotion was observed for the biofilm samples 
containing relatively low concentrations of agents (20 µM and 40 µM). While at 340 µM, 
around 80 % of the biofilms were inhibited by DβM, BPDeβM, SFβM, and SFβC.  
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Figure 3.7 The effect of rhamnolipid analogs on biofilm formation by the rhlA mutant of 
P. aeruginosa (A) in 24 h, and (B) in 48 h under 100 rpm shaking condition. 
Representative confocal laser scan microscopy (CLSM) images of biofilm formed by 
rhlA-EGFP strain (plasmid pSMC2 that expresses green fluorescence). Scale bar = 76 
µm.  
 
We note that in a 24 well-Plate under shaking conditions, the biofilm formed by 
the rhlA mutant in the presence of saturated farnesol agents exhibited a conspicuously 
different appearance than the biofilm formed without added agents.  Without added 
agents, the biofilms formed by rhlA mutant appeared to have more exopolymers covering 
the bottom of the wells, whereas, with SFβM at both low (20 µM) and high (85 µM) 
concentrations, there were fewer exopolymers covering the bottom of the wells (Figure 
3.8). For C6OC5βC and C3OC8βC, there is no significant change in the number of 
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fluorescent signals in the biofilm formed by rhlA-EGFP strain as compared to the control 
that has no added agents (Figure 3.9).  
 
 
Figure 3.8 Treatment of rhamnolipids analogs on rhlA mutant affects the appearance of 
biofilm formed on 24 well plates under non-shaking condition. 
 
Figure 3.9 The effect of rhamnolipids analogs on biofilm formation by the rhlA mutant of 
P. aeruginosa in 48 h under 100 rpm shaking condition. Representative confocal laser 
scan microscopy (CLSM) images of biofilm formed by rhlA-EGFP (plasmid pSMC2 that 
expresses green fluorescence). Scale bar = 76 µm.  
 52 
 
 
Next, we examined the biofilm formed by the rhlA mutant with intermediate 
concentrations between the low concentrations that caused the initial promotion and the 
high concentrations that caused the biofilm inhibition. To our surprise, at intermediate 
concentrations, the synthetic analogs SFβM (40 µM), SFβC (40 µM), and BPDeβm (40 
µM) promoted biofilms formed by rhlA mutant to exhibit structural features of porosity 
more resembling the structured PAO1 biofilm formed under shaking than that without 
shaking (Figure 3.10).  Without shaking, these structural features in the biofilm of rhlA 
mutant are likely caused by the presence of synthetic analogs rather than any other 
physical effect. 
 
Figure 3.10 The effect of synthetic analogs of rhamnolipids on biofilm formation by the 
rhlA mutant of P. aeruginosa in 24 h under non-shaking condition. Representative 
confocal laser scan microscopy (CLSM) images of biofilm formed by rhlA- EGFP strain 
(expresses green fluorescence on plasmid pSMC2). Scale bar = 76 µm.  
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Wild-type PAO1 produces rhamnolipids, and under a flowing fluid8 or shaking 
conditions, produces highly structured biofilms with channels. For rhlA mutant which 
does not produce rhamnolipid, however, our shaking experiment does not cause the 
bacteria to produce structured biofilm. Instead, two notable rhamnolipid analogs, SFβM 
and SFβC, at intermediate concentrations enabled rhlA mutant to make structured 
biofilms without shaking or under a flowing fluid. Figure 3.11 summarizes the effect of 
active synthetic analogs on biofilm structures of rhlA mutants. These fluid-filled voids 
give rise to the complex structure in a biofilm including pores and channels. Such 
structures are believed to be responsible for nutrient transport, cell-cell interactions, and 
even to support a degree of homeostasis.36 The mechanism for the formation of these 
structures is still unclear although we know that rhamnolipids, and also its synthetic 
analogs, play a critical role.   
 
 
Figure 3.11  Schematic representation of synthetic analogs of rhamnolipids at modulating 
biofilm formed by the rhlA mutant. 
Biofilm formation and swarming motility are both multi-cellular activities, and 
many of these multi-cellular activities are initiated or regulated by quorum sensing.154-156 
Here, we believe that both biofilm formation and swarming motility are also controlled 
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by chemical cues or signals such as rhamnolipids from the environment. These signals 
directly control whether swarming motility will occur or not, and what types of the 
internal structures of biofilm will be formed. It is not clear whether rhamnolipids and the 
synthetic analogs in our studies,136, 138 are just signaling molecules that trigger the 
formation of pores and channels; or whether they also take part as a structural component 
to build and maintain the fluid void structures in a biofilm; or, whether they also act as 
anchors to which the bacteria attach in a biofilm. This subject is an ongoing area of 
research in our studies.  
 
 3.3. Conclusions 
In this work, we found that synthetic rhamnolipid-analogs active for controlling 
swarming (inhibition and activation) also promote biofilm formation of a non-swarming 
strain, rhlA mutant, at relatively low concentration, but inhibit biofilm formation at high 
concentration. Agents that are inactive at controlling swarming motility are also not 
active in influencing the biofilm formation of the rhlA mutant. We also find that biofilm 
of PAO1 under shaking conditions exhibited porous structures, whereas under static 
conditions showed relatively uniform biofilms. Using this result as criteria for 
comparison between structured and nonstructured biofilms, we find that biofilm 
formation caused by the presence of rhamnolipid-analogs at intermediate concentrations 
also exhibited porous features. Together, these results suggest that synthetic rhamnolipid-
analogs behave as signaling molecules and can substitute rhamnolipids for functional 
control. Among many other approaches,157-158 chemical signaling that governs the 
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quorum sensing of bacteria has been a target for developing anti-bacterial as well as 
potential therapeutic agents.147, 154, 159 We believe that a new approach of developing 
mimics and dominating agents of the environmental cues bears an enormous potential for 
developing therapeutic agents and chemical applications.  
3.4 Materials and methods  
 
3.4.1. Synthetic procedure  
 
Synthesis of C6OC5OH: 0.51 g (12.9 mmol) of NaH (60% dispersion in mineral 
oil) was suspended in 10 mL of DMF and added to a solution of pentan-1,5-diol (2.69 g, 
25.8 mmol) in DMF (6 ml). 1-bromohexane (1.33 g, 8.06 mmol) was then added drop by 
drop under argon and stirred overnight. The reaction mixture was quenched with 
deionized water and extracted with 1:1 hexane and ethyl acetate. Then the organic phase 
was concentrated in vacuo at 35 °C. The crude product was then purified by column 
chromatography. The product was obtained as colorless oil, 1.17 g, 73 %, Rf = (0.35, 45 
% EtOAc in Hexane). 1H NMR (400 MHz, CDCl3): δ 3.63 (t, 2H), 3.38 (t, 2H), 3.36 (t, 
2H), 1.70-1.21 (m, 14H), 0.88 (t, J= 6.3 Hz, 3H). HRMS (ESI+): Cacld. for M+: 
189.1776, found: 189.1853  
  
Synthesis of C3OC8OH:  0.51 g (12.9 mmol) of NaH (60% dispersion in mineral 
oil) was suspended in 10 mL of DMF and added to a solution of octan-1,8-diol (3.77 g, 
25.8 mmol) in DMF (6 ml). 1- bromopropane (0.99 g, 8.06 mmol) was then added drop 
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by drop under argon and stirred overnight. The reaction mixture was quenched with 
deionized water and extracted with 1:1 hexane and ethyl acetate. Then the organic phase 
was concentrated in vacuo at 35 °C. The crude product was then purified by column 
chromatography. C3OC8OH was obtained as colorless oil, 1.13 g, 69 %, Rf = (0.37, 45 % 
EtOAc in Hexane). 1H NMR (400 MHz, CDCl3): δ 3.63 (t, 2H), 3.36 (t, 2H), 3.34 (t, 
2H), 1.66-1.20 (m, 14H), 0.88 (t, J= 6.3 Hz, 3H). HRMS (ESI+): Cacld. for M+: 
189.1776, found: 189.1853 
 
Synthesis of acetylated-bromo-cellobiose: To an oven-dried round bottom flask, 
cellobiose (1.0 g, 2.8 mmol), AcBr (~3.6 mL, 44.4mmol), and AcOH (19 mL) were 
added and stirred at room temperature (25 °C) for ~ 1 h. The reaction mixture was 
concentrated in vacuo at 35 ⁰C and then co-evaporated three times with PhMe (2×10 mL, 
anhydrous). After removal of solvent, the flask was further heated in vacuo at 50 ⁰C for 
15min to give a foamy solid, aceto-bromo-cellobiose. The crude aceto-bromo cellobiose 
was immediately used in next step without any further purification.  
  
Synthesis of acetylated C6OC5βC and acetylated C3OC8βC: For obtaining β-
anomer as the major product, the crude aceto-bromo cellobiose was dissolved in MeCN 
(10 mL) and 2 equivalents of C6OC5OH (1.05 g, 5.6 mmol) or C3OC8OH (1.05 g, 5.6 
mmol) were added along with two equivalents of FeCl3 (5.6 mmol). The reaction mixture 
was stirred vigorously for about ~45-60 mins at rt. After stirring at rt, aq KBr (10%, 25 
mL) and then toluene (60 mL) were added under stirring. The organic phase was washed 
twice with aq KBr (10 %, 2×25 mL), once with aq NaHCO3 (5 %, 25 mL) and twice with 
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H2O (2×25 mL). The crude product was then purified by column chromatography using 
gradient elution (100 % hexane to 40 % ethyl acetate in hexane).  Acetylated C6OC5βC 
was obtained as Colorless powder, 0.42 g, 21.3 % (2-step), Rf = (0.36, 40 % EtOAc in 
Hexane). 1H NMR (400 MHz, CDCl3): δ 5.20 (m, 3H), 4.93 (q, J1-2 = 8.4 Hz, 2H), 4.54-
4.43 (m, 3H), 4.39 (dd, J1-3 = 12.9 Hz, J1-2 = 4.8 Hz, 1H), 4.13-4.02 (m, 2H), 3.87- 3.74 
(m, 2H), 3.69-3.56(m, 2H), 3.44 (q, 1H), 3.38 (t, 2H) 3.36 (t, 2H) 2.13-1.99 (s, 7 X 3H), 
1.70-1.21 (m, 14H), 0.88 (t, J= 6.3 Hz, 3H). Acetylated C3OC8βC was obtained as 
colorless powder, 0.50 g, 23.1 % (2-step), Rf = (0.42, 40 % EtOAc in Hexane). 1H NMR 
(400 MHz, CDCl3): δ 5.20 (m, 3H), 4.93 (q, J1-2 = 8.4 Hz, 2H), 4.54-4.43 (m, 3H), 4.39 
(dd, J1-3 = 12.9 Hz, J1-2 = 4.8 Hz, 1H), 4.13-4.02 (m, 2H), 3.87- 3.74 (m, 2H), 3.69-
3.56(m, 2H), 3.44 (q,  1H), 3.36 (t, 2H), 3.34 (t, 2H), 1.66-1.20 (m, 14H), 0.88 (t, J= 6.3 
Hz, 3H). 
 
Synthesis of C6OC5βC and C3OC8βC: The deprotection of acetyl groups was 
achieved by Zemplén deacetylation using MeONa/MeOH (10 mM solution) conditions 
followed by neutralization (pH ~6.5) over H+ amberlite resins. The resins were filtered 
off and products dried under high vacuum overnight. C6OC5βC was obtained as colorless 
powder, 0.23 g, 87 %. 1H NMR (300 MHz, CD3OD): δ 4.36 (d, J = 7.8 Hz, 1H), 4.28 (d, 
J = 7.8 Hz, 1H), 3.82 (m, 4H), 3.69-3.47 (m, 4H), 3.40-3.25(m, 8H, overlapping with 
MeOH), 3.18-3.11 (m, 2H), 1.60-1.13 (m, 14H), 0.82 (t, J= 6.3 Hz, 3H). 13C NMR (100 
MHz, CD3OD): δ 103.2, 102.8, 79.3, 76.7, 76.4, 75.1, 75.0, 73.7, 73.5, 70.7, 70.4, 69.9, 
69.3, 61.4, 60.5, 31.4, 29.3, 29.2, 29.1, 25.5, 22.3, 22.1, 13.0. HRMS (ESI) m/z: Calcd. 
(C23H44O12)Na
+: 535.2731; Found: 535.2728. C3OC8βC was obtained as colorless 
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powder, 0.24 g, 91 %. 1H NMR (300 MHz, CD3OD): δ 4.33 (d, J = 7.8 Hz, 1H), 4.19 (d, 
J = 7.8 Hz, 1H), 3.78 (m, 4H), 3.63-3.39 (m, 4H), 3.40-3.25(m, 8H, overlapping with 
MeOH) 1.66-1.20 (m, 14H), 0.85 (t, J= 6.3 Hz, 3H). 13C NMR (100 MHz, CD3OD): δ 
103.2, 102.8, 79.3, 76.7, 76.4, 75.1, 75.0, 73.7, 73.4, 72.1, 70.4, 69.9, 69.3, 61.4, 60.5, 
29.3, 29.3, 29.1, 29.1, 25.8, 25.6, 22.5, 9.5. HRMS (ESI) m/z: Calcd. (C23H44O12)Na
+: 
535.2731; Found: 535.2728. 
3.4.2. Bacterial strains     
 
Wild-type P. aeruginosa PAO1 and PAO1-EGFP strains were obtained from Dr. 
Guirong Wang (Upstate Medical University, Syracuse). The non-swarming mutant of P. 
aeruginosa, rhlA (PW6886, rhlA-E08::ISphoA/hah) was obtained from PA two-allele 
library (PAO1 transposon mutant library).156 
3.4.3. Crystal violet dye-based biofilm inhibition assay    
 
Inhibitory effect of all the maltose hydrocarbons on the biofilm formation by rhlA 
mutant was determined by crystal violet dye based biofilm inhibition assays. An 
overnight culture of the rhlA mutant was subcultured to an OD600 of 0.01 into the LB 
medium. 200 µL of the subculture was aliquoted into the wells of 96-well polystyrene 
microtiter plate when it reached the OD600 of 0.1. Predetermined concentrations of the 
test compounds were then added to the respective wells containing subculture. Sample 
plates were wrapped in GLAD Press n’ Seal® followed by incubation under stationary 
conditions for 24 h at 37 °C. After incubation, the media was discarded and the plates 
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were washed with water and dried for 1 h at 37 °C. The sample plates were stained with 
200 μL of 0.1% aqueous solution of crystal violet (CV) and followed by incubation at 
ambient temperature for 20 min. The CV stain was then discarded and the plates were 
washed with water. The remaining biofilm adhered stain was re-solubilized with 200 μL 
of 30 % acetic acid. After the stain was dissolved (15 minutes), 100 μL of the solubilized 
CV was transferred from each well into the corresponding wells of a new polystyrene 
microtiter dish. Biofilm inhibition was quantified by measuring the OD600 of each well in 
which a negative control lane wherein no biofilm was formed served as a background and 
was subtracted out. The percent inhibition was calculated by the comparison of the OD600 
for biofilm grown in the absence of compound (control) versus biofilm grown in the 
presence of compound under identical conditions. Biofilm inhibition assay with all the 
maltose derivatives was repeated four times and each data point in the graph is the 
average of values from 6 wells. 
 
3.4.4. Confocal laser scanning microscopy (CLSM)     
 
Biofilms were grown by inoculating the bacteria on polystyrene coupons (3/8 in. 
× 3/8 in.) with or without rhamnolipid analogs in a 24-well microtiter plate. The saran-
wrapped plate was then incubated at 37 oC with or without shaking. Each polystyrene 
coupon was then washed gently by dipping into 0.85 w/v% aqueous NaCl solutions twice 
and then placed on a microscope cover glass (50 x 24mm, No. 2, Fisher Scientific, 
Pittsburgh, PA). The biofilms were visualized using a Zeiss LSM 710 Confocal Laser 
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Scanning Microscope (Carl Zeiss, Jena, Germany). A 488 nm laser line was used to 
visualize biofilms formed by PAO1-EGFP and rhlA-EGFP strains.  
3.4.5. Biofilm inhibition assay 
 
An overnight culture of rhlA strain was subcultured to an OD600 of 0.01 in the LB 
medium. 200 µL of the subculture was aliquoted into the wells of 96-well polystyrene 
microtiter plate when it reached the OD600 of 0.1. The stock solutions of the test 
compounds in sterile water were added to the wells containing the subculture to achieve 
the predetermined concentrations. Sample plates were wrapped in polyvinylidene 
chloride (PVDC) and incubated without shaking for 24 h at 37 °C. After incubation, the 
media was discarded and the plates were washed with water and dried for 1 h at 37 °C. 
200 µL of LB media and the test compounds were then added to the corresponding wells 
again. Sample plates were wrapped in PVDC and incubated without shaking for another 1 
h at 37 °C. 100 μL of the media from each well was transferred into the corresponding 
wells of a new polystyrene microtiter plate. And the OD600 of each well was read by a 
microplate reader Elx800 (BIO-TEK Instruments, Inc., Winooski, VT, USA). A control 
lane containing pure LB media served as a background and was subtracted out. The 
percent bacteria in the biofilm was calculated by the comparison of the OD600 for bacteria 
grown in the absence of compound (control) versus bacteria grown in the presence of 
compound under identical conditions. Each data point in the graph is the average of 
values from 6 wells. 
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1H NMR spectra 
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13C NMR Spectra 
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HRMS Spectra 
 
HRMS (ESI+): Cacld. for M+: 189.1776, found: 189.1853 
 
HRMS (ESI+): Cacld. for M+: 189.1776, found: 189.1853 
 
HRMS (ESI) m/z: Calcd. (C23H44O12)Na
+: 535.2731; Found: 535.2728. 
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HRMS (ESI) m/z: Calcd. (C23H44O12)Na
+: 535.2731; Found: 535.27  
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Chapter 4 Synthetic Disaccharide Derivatives Inhibit Bacterial Antibiotic-Promoted 
Activities and Increase the Potency of Antibiotics to Remove Biofilms* 
4.1. Introduction 
4.1.1. A brief introduction of antibiotic resistance, tolerance, and persister 
 
Antibiotic-treatment failure is typically attributed to antibiotic resistance.77, 160 
“Resistance” is used to describe the inherited ability of microorganisms to grow at high 
concentrations of an antibiotic, and can be quantified by the minimum inhibitory 
concentration (MIC) of the particular antibiotic,161 Resistance is most often thought of as 
being attributable to mutations or exchange of antibiotic resistance genetic elements, 
although resistance may also be intrinsic and thus dependent on wild-type genes and 
innate properties of the cell.162-163 For example, Gram-negative bacteria are intrinsically 
more resistant than Gram-positive cells to certain antibiotics like vancomycin due to the 
relatively less outer membrane permeability. Resistance mechanisms have been described 
by Lewis164 as the means by which an antimicrobial agent is prevented from interacting 
with its intended target including antibiotic efflux pumps,165 molecules (such as eDNA166 
and NdvB-derived periplasmic glucans167) that sequester antibiotics, and matrix β-
lactamases168. 
In contrast, “tolerance”, which is defined by Kester and Fortune, is used to 
describe the ability of microorganisms to survive transient exposure to high 
concentrations of an antibiotic without a change in the MIC, which is often achieved by 
                                                 
* The work in this chapter is a collaboration with Felicia Burns in Luk group. She synthesized and 
characterized the two molecules, 3,5-DMDβM and 3,5-DMDβC, used in this chapter. 1HNMR and 
13CNMR collected by Felicia Burns were included for the purpose of completing the information. 
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slowing down an essential bacterial process.169-170 In the presence of the antibiotic, 
tolerant bacteria cease to grow; however, they can start to grow and replicate once the 
antibiotic is removed.171 Tolerance is an inherited rather than a non-inherited form of 
antibiotic resistance; tolerant cells are genetically different to the non-tolerant bacteria 
from which they are derived.172-175 A measure of tolerance is the minimum bactericidal 
concentration (MBC), which is the lowest concentration of a bactericidal antimicrobial 
that will kill ≥99.9% of cells in a culture.176 Mechanisms of tolerance are thought to 
somehow prevent the bactericidal agent from exerting its downstream toxic effects even 
though the agent has bound to its target.164 Based on this definition,  antibiotic tolerance 
mechanisms include reduced growth rate177-178, the mechanisms that handle antibiotic-
induced oxidative stress179 and persister cells180. 
In contrast to resistance and tolerance, which are attributes of whole bacterial 
populations, ‘persistence’ is a term that describes the ability of a subpopulation of a 
clonal bacterial population to survive exposure to high concentrations of an antibiotic.181 
Persistence, was first reported for staphylococcal infections treated with penicillin and 
has since been observed in many bacterial species.182 Despite being observed almost for 
decades, the mechanism behind persistence remains a puzzle. The reason might due to 
technical difficulties of working with a small fraction of cells expressing a temporary 
phenotype of uncertain functional significance.183-184 In the 1980s, Harris and coworkers 
continued working on to search for genes that caused persister formation.185-188 One of 
these persister mutations was mapped to the hipA gene. The hipA7 allelic strain produced 
~1% persisters that survived treatment with ampicillin in exponential cultures, which is 
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approximately 1,000 times more persisters than the wild-type strain. The recent discovery 
of persisters in biofilms has led to a great interest in studying those unusual cells.180, 189 
Bacteria have the potential to adapt to the environment, either under natural or 
laboratory condition.190 Recent studies have shown that tolerance and persistence evolve 
rapidly under intermittent antibiotic exposure. Nathalie and coworkers reported resistance 
enhancement in bacterial populations under cyclic antibiotic treatments.191 Maarten and 
Jan demonstrated that persistence is a highly evolvable trait that quickly adapts to drug-
treatment frequency,192 and that its evolutionary dynamics can be understood in the 
context of bet-hedging theory.193-197 Hinrich and Gunther reported that P. aeruginosa 
adapts rapidly to high-level antibiotic stress and they expressed both collateral sensitivity 
and cross-resistance which was revealed by genomic and functional genetic analysis.198 
Evolution of resistance from tolerance indicates that new drugs or their combinations that 
decrease tolerance may intervene in the resistance evolution process. 
4.1.2. The effect of sub-MIC antibiotics on P. aeruginosa biofilm formation 
Pseudomonas aeruginosa forms biofilm with extreme tolerance to antibiotics in 
nosocomial infections, such as pneumonia and surgical site infections. The Diseases 
Society of America declared Pseudomonas aeruginosa is one of the six ‘top-priority 
dangerous, drug-resistant microbes.199 More than 60% of the bacterial infections 
currently treated by physicians are considered to involve biofilm formation.128 Successful 
treatment in these cases depends on the effective removal of those biofilm materials. 
Since the discovery of penicillin, antibiotics have been proven to be effective in 
controlling serious bacterial infections.63 Microbiologists have been using minimal 
inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) to 
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assess the effect of antibiotics against planktonic organisms. Table 4.1 showed MIC and 
MBC of 6 different antibiotics toward P. aeruginosa. As mentioned in chapter 1, 
antibiotics can act as signaling molecules that trigger transcription responses important 
for environmental survival in low concentrations.75-76 While the growth of surrounding 
microorganisms could be inhibited at high concentrations of antibiotics are present.77 
Various studies have shown that sub-minimal inhibitory (sub-MIC) concentrations of 
some antibiotics can inhibit biofilm formation without killing the bacteria. Ichimiya and 
coworkers found that azithromycin can efficiently inhibit Pseudomonas aeruginosa 
biofilm formation at 1/128 of the MIC.200-201 Low dose azithromycin therapy has been 
shown to improve lung function in cystic fibrosis patients.202-204 The effect of low-dose 
azithromycin chemotherapy may be due to its ability to inhibit quorum sensing and 
alginate production of mucoid biofilms at sub-MIC concentrations.205-207 
Table 4.1 MIC and MEC of different antibiotics for P. aeruginosa 
 
Antibiotic 
MIC 
(mg/L) 
 
MBC 
(mg/L) 
 
Primary target 
 
Aztreonam 
 
2208/16209 
 
- Penicillin-binding proteins 
 
Chloramphenicol 
 
- 1024210 
 
50S ribosome (Protein translation) 
 
Tetracycline 
 
- 512211 
 
30S ribosome (Protein translation) 
 
Ciprofloxacin 
 
1212 
 
4213 
 
Topoisomerase II (DNA gyrase), 
topoisomerase IV 
 
Colistin 
 
8~16214 
 
64~128214 
 
Cell membrane 
 
Tobramycin 
 
1215 ~53210 
 
30S ribosome (Protein translation) 
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However, there are numerous studies have shown that some antibiotics can induce 
biofilm formed by P. aeruginosa when present at concentrations below the MIC. Garey and 
coworkers216 showed that sub-MIC concentrations of clarithromycin induced biofilm 
formation by 25-fold in 44 P. aeruginosa clinical isolates when tested at 1/32 to 1/2 MIC. 
Linares and coworkers217 found that sub-MIC concentrations of tobramycin, ciprofloxacin, 
and tetracycline-induced P. aeruginosa biofilm formation by approximately 2-fold. Bagge 
and coworkers218 also used microarray technology to study the effects of sub-MIC 
concentrations of the β-lactam antibiotic imipenem on P. aeruginosa biofilm formation. 
They identified 34 genes that were induced or repressed in biofilms exposed to 1/2 MIC 
imipenem. Five alginate metabolism-related genes (algD, algG, algJ, algF, and algA) were 
induced more than 10-fold by imipenem at 1/2 MIC. Hoffman and coworkers42 found that 
sub-MIC concentrations of tobramycin readily induced P. aeruginosa biofilm formation 
while several other antibiotics including polymyxin B, chloramphenicol and carbenicillin 
had no effect on biofilm formation.42 They found that all the mutants carried transposon 
insertions in a gene designated arr, which is an aminoglycoside response regulator that 
encodes a c-di-GMP phosphodiesterase that degrades c-di-GMP and reduces intracellular 
c-di-GMP concentrations, were defective in tobramycin-induced biofilm formation.42 The 
results suggested that Aminoglycoside antibiotics such as tobramycin could act as first 
messengers that trigger changes—mediated either by binding directly to proteins such as 
Arr or indirectly through intermediary molecules—in the level of the second messenger c-
di-GMP.42  
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4.1.3. Puzzle: Biofilm formation and swarming motility are inversely regulated but both 
activities can be induced by antibiotics 
 
Switching between sessile and motile states is an important decision for the 
bacteria to ensure its survival.48 However, external environmental stimuli that cause the 
transition from sessile to motile mode still remains unclear.48, 219-220 As both swarming 
and biofilm formation are surface-associated multicellular behaviors that are controlled 
by bacterial quorum sensing, it is important to understand the relation between the two 
behaviors. SadB was originally identified as required for early biofilm formation, is also 
a negative effector of swarming motility. O’Toole and co-workers found that sadB gene 
of P. aeruginosa is most likely responsible for inversely regulating the swarming and 
biofilm formation through the chemotaxis cluster IV.221-222 The authors also proposed that 
P. aeruginosa inversely regulates the surface-associated behaviors of biofilm formation 
and swarming by controlling both flagellar reversals and the production of the Pel 
polysaccharide. It has been observed that during the biofilm formation process bacterial 
cells were switched from one lifestyle to another to adapt to the new lifestyle.223 For 
instance, during the biofilm formation process the cells of P. aeruginosa usually develop 
single polar flagella to assist the surface adherence process, while during swarming, P. 
aeruginosa seems to develop two polar flagella.43, 219  
There are numerous studies have shown that antibiotics not only induce biofilm 
formation it can also induce swarming motility of P. aeruginosa when present at 
concentrations below the MIC. Hoffman and coworkers42 found that sub-MIC 
concentrations of tobramycin readily induced P. aeruginosa biofilm formation. Garey and 
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coworkers216 showed that sub-MIC concentrations of clarithromycin induced biofilm 
formation by 25-fold in 44 P. aeruginosa clinical isolates when tested at 1/32 to 1/2 MIC. 
Linares and coworkers found that sub-MIC of tobramycin increased bacterial swarming 
motility.217 However, the mechanism of antibiotics inducing P. aeruginosa biofilm 
formation and swarming motility is still unclear. 
 
4.1.4. The aim of the chapter 
 
In this chapter, we have examined the effect of our synthetic disaccharide 
derivatives on sub-MIC antibiotic-promoted biofilm formation and swarming motility. 
The preliminary investigation by our previous lab members brought forward the 
hydrocarbon maltoside and cellobioside derivatives as potent biofilm and swarming 
inhibitors. Additionally, the fact that many saccharide-hydrocarbons are involved in 
bacterial surface recognition events further prompted us to explore the effect of our 
synthetic SFβM along with other potent leads 3,5-DMDβM and 3,5-DMDβC on sub-MIC 
antibiotic-promoted biofilm formation and swarming motility. Furthermore, we have 
examined the efficacy of two compounds SFβM and SF(EG)4OH in enhancing the 
bactericidal action of antibiotics colistin and tobramycin on biofilms grown on a 
polystyrene surface. In addition, to study drug tolerance and persister formation, we 
examined the ability of our molecules to eradicate drug tolerance and persisters induced 
by the presence of antibiotics using resazurin dye-based cell viability assay. To study the 
effect of our synthetic molecules, 3,5-DMDβM and 3,5-DMDβC, on the efficacy of 
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antibiotics to combat tobramycin-tolerant subpopulations, we examined the live and dead 
subpopulation of native and tobramycin promoted biofilms by confocal laser scanning 
microscope (CLSM).  
 
4.2. Results and discussion 
4.2.1. Library of molecules used in this study 
 
In order to investigate the effect of our synthetic molecules on inhibiting 
antibiotic-promoted bacterial activities and increase the potency of antibiotics to kill 
bacteria in biofilms, a library of molecules was tested which has been listed in Figure 4.1.  
2-ABI is a commercially available molecule. SF(EG)4OH and SFβM were designed and 
synthesized by our previous lab member Nischal. 3,5-DMDβM and 3,5-DMDβC were 
designed and synthesized by our current lab member Felicia Burns.  
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Figure 4.1 Collection of molecules used in this study. 3,5-DMDβM and 3,5-DMDβC are 
synthesized and characterized by Felicia Burns. 
4.2.2. Disaccharide molecules having branched hydrocarbons inhibit tobramycin-
promoted bacterial activities 
Biofilm formation and swarming motility are two critical pathogen-related 
functions of bacteria.221 Below the lethal concentration, tobramycin promotes both 
bioactivities by P. aeruginosa.100  In contrast, our potent lead compound, SFβM, inhibit 
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both biofilm formation and swarming motility. The mechanism for these observations is 
not yet clear, but we have identified two proteins to which SFβM binds: Lectin A and pilin, 
which I will describe in detail in chapter 5 and 6. Here, we examined the influence of 
synthetic disaccharide derivatives supplemented with Las quorum sensing inhibitor ABI 
on normal biofilm and sub-MIC of tobramycin promoted biofilm formed by PAO1-EGFP 
strain under slow shaking condition (100 rpm). Biofilm inhibition activity of active 
disaccharide derivatives was verified by fluorescence-based biofilm assay.  P. aeruginosa 
strain, PAO1-EGFP that constitutively expresses a green fluorescent protein (GFP) was 
allowed to grow on sterile polystyrene coupons for 24 h. The biofilms formed on the 
coupons grown in the presence and in absence of maltose derivatives were viewed under 
confocal laser scanning microscope (CLSM). The fluorescence observed indirectly 
indicates the amount of biofilm formed on the coupons. The biomass of biofilm was 
quantified using COMSTAT software. At 24 h, there is visibly less fluorescence signal for 
biofilm formed by the PAO1-EGFP strain which was treated with 40 µM SFβM/ABI, than 
biofilm formed without any added agents (Figure 4.2). For the sub-MIC of tobramycin 
promoted biofilm, there is visibly more fluorescence signal compared to biofilm formed 
without any added agents (Figure 4.2). In addition, adding 40 µM SFβM/ABI along with 
0.3 µg/mL tobramycin, biofilms formed significantly less than sub-MIC of tobramycin 
promoted biofilm based on fluorescence signals. These results suggest that SFβM not only 
inhibited normal biofilm formed by PAO1-EGFP it also inhibited sub-MIC of tobramycin 
promoted biofilm. However, the remained portion of sub-MIC of tobramycin promoted 
biofilm after grown with 40 µM SFβM is still more than the remaining portion of 40 µM 
SFβM/ABI treated normal biofilm formed by PAO1-EGFP.  
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Figure 4.2 Representative confocal laser scanning microscopy (CLSM) micrographs of 
biofilm formed by PAO1-EGFP without (A) and with (B) Tobramycin (Tob) at a sub-MIC 
(0.3 μg/mL). Adjuvant molecules SFβM & 2-amino benzimidazole (2-ABI) (40 µM each) 
inhibit both native (C) and tobramycin-promoted biofilm (D). Biofilms were grown on 
polystyrene for 24 h with shaking (100 rpm). Scale bar = 30 μm. The thickness and biomass 
of biofilm were quantified using COMSTAT software. 
Furthermore, the CLSM images show that the biofilm formed on the coupons in 
presence of 3,5-DMDβM and 3,5-DMDβC were significantly lower than those formed 
without agents (Figure 4.3). In the presence of 0.3 µg/mL tobramycin, which is the optimal 
condition for forming a sub-MIC antibiotic-promoted biofilm, the thickness was increased 
around 30%. When adding disaccharide derivatives, 3,5-DMDβM and 3,5-DMDβC, the 
thickness of the sub-MIC antibiotic-promoted biofilm were significantly decreased by 
around 50%.  
PAO1
-EGFP
w/o
Tob.
+ 40 
μM 
SFβM/  
ABI
A C
DB
w/ 
Tob.
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Figure 4.3 Representative confocal laser scanning microscopy (CLSM) micrographs of 
biofilm formed by PAO1-EGFP on polystyrene coupons; biofilms on the first row were 
grown in the absence of agents(control), and in the presence of 85 μM 3,5-DMDβM and 
3,5-DMDβC. * Biofilms on the second row were grown under the same condition as the 
first row plus 0.3 µg/mL Tobramycin. Bacterial strain: PAO1-EGFP; Initial OD600: 
0.01; Surface: Polystyrene; Time: 24 h; Shaking speed: 100 rpm; Scale bar: 30 µm. The 
thickness and biomass of biofilm was quantified using COMSTAT software. 
                                                 
* The work in this chapter is a collaboration with Felicia Burns in Luk group. She synthesized and 
characterized the two molecules, 3,5-DMDβM and 3,5-DMDβC, used in this chapter. 1HNMR and 
13CNMR collected by Felicia Burns were included for the purpose of completing the information. 
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In addition, we examined the eradication effect of SFβM and amino 
benzimidazole on preformed native and tobramycin promoted biofilms. Specifically, we 
first grow a biofilm of PAO1-EGFP strain with and without 0.3 µg/mL of tobramycin for 
24 h to establish an antibiotic-promoted biofilm and a native biofilm, respectively. For 
each biofilm, we then introduced fresh LB medium with and without 40 µM of SFβM or 
40 µM 2-ABI or both. The thickness and biomass of biofilm were quantified using 
COMSTAT software. The results showed that during this second culture period, around 
30-40 % of native biofilm was eradicated when 40 µM of SFβM was added. The biofilm 
thickness was decreased ~25% as well. However, 40 µM 2-ABI did not have any 
significant effect on either biofilm thickness or the biomass. Furthermore, the effect of 
adding both 40 µM of SFβM and 40 µM 2-ABI is similar to adding 40 µM of SFβM 
alone (Figure 4.4). 
Eradication effect of SFβM and amino benzimidazole on preformed tobramycin 
promoted biofilms was tested using the similar way above. The results showed that 
during this second culture period, around 25 % of tobramycin promoted biofilm was 
eradicated when 40 µM of SFβM was added. However, the biofilm thickness was only 
decreased by ~10 %. 40 µM 2-ABI did not have any significant effect on either biofilm 
thickness or the biomass. Furthermore, the effect of adding both 40 µM of SFβM and 40 
µM 2-ABI is similar to adding 40 µM of SFβM alone (Figure 4.5). The reason why 
antibiotic-promoted biofilms were slightly more difficult to eradicate than native biofilms 
is probably due to certain exopolymer acting as physical barriers and reduce the 
penetration of antibiotic into the deep part of biofilms, which allows more biofilm cells to 
survive and acquire tolerance.214 
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Figure 4.4 Representative confocal laser scanning microscopy (CLSM) micrographs of 
biofilm formed by PAO1-EGFP. Adjuvant molecules SFβM & amino benzimidazole 
(ABI) (40 µM each) inhibit native biofilm formation. Biofilms were grown on 
polystyrene for 24 h with shaking (100 rpm). Scale bar = 30 μm. The thickness and 
biomass of biofilm were quantified using COMSTAT software. 
 
 
 
 85 
 
 
                
Figure 4.5 Representative confocal laser scanning microscopy (CLSM) micrographs of 
biofilm formed by PAO1-EGFP with Tobramycin (Tob) at a sub-MIC (0.3 μg/mL). 
Adjuvant molecules SFβM & amino benzimidazole (ABI) (40 µM each) inhibit 
tobramycin-promoted biofilm formation. Biofilms were grown on polystyrene for 24 h 
with shaking (100 rpm). Scale bar = 30 μm. The thickness and biomass of biofilm were 
quantified using COMSTAT software. 
Swarming is a complex mode of translocation that is fundamentally different from 
other bacterial motilities like swimming and twitching. It has been reported that P. 
aeruginosa requires all of the following features to successfully swarm on a semisolid 
surface; quorum sensing, flagella, pili and production of biosurfactant rhamnolipids.219  
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PAO1 strain used in this study grows outward from the point of inoculation without 
forming any tendril patterns. Here, we examined the influence of synthetic disaccharide 
derivatives on normal and sub-MIC of tobramycin promoted swarming of PAO1 strain. It 
is evident from the images of swarm agar plates that the area or the diameter of PAO1 
added with 20 µM SFβM was significantly smaller than PAO1 control without adding 
any agents (Figure 4.6). However, when adding 0.3 µg/mL of tobramycin, the swam area 
is slightly bigger than PAO1 control without adding any agents which indicate that the 
swarming of PAO1 is promoted by tobramycin. Furthermore, adding 20 µM SFβM along 
with 0.3 µg/mL of tobramycin significantly inhibits swarming of PAO1(Figure 4.6). 
 
 
 
 
 
 
 
 
 
Figure 4.6 Swarming of PAO1 (A) is promoted by tobramycin (0.3 µg/mL) (B). Adding 
20 µM SFβM to the swarm plates inhibits swarming without (C) and with (D) added 
tobramycin.  
+ 20 
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SFβM 
in gel
A C
DB
PAO1
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4.2.3. Synthetic agents acting as adjuvant compounds to enhance the activity of 
antibiotics against bacteria in biofilms on an abiotic surface 
 
We also assessed the ability of our compounds to facilitate the killing of pre-
formed biofilms in our co-culture model of PA biofilms on polystyrene surfaces. Here, 
we tested two antibiotics, colistin, and tobramycin, which were proven to be most 
effective against PA bacteria (see Figure 4.7). In this assay, biofilms were grown on 
polystyrene surfaces for 24 h to reach the mature state. Then predetermined 
concentrations of antibiotics (25 µg/mL, 30 µg/mL, 35 µg/mL colistin and 8 µg/mL, 16 
µg/mL, 32 µg/mL tobramycin) and agents (50 µM SFβM and 50 µM SF(EG)4OH) were 
added to those pre-formed biofilms and incubated for another 24 h. Survived bacteria 
were quantified by OD600 readings. For colistin, added synthetic agents significantly 
enhanced the efficacy of the antibiotics. When SFβM or SF(EG)4OH were added to 25 
µg/mL and 35 µg/mL colistin, the survived bacteria within the biofilms were decreased 
by 75-85 % (Figure 4.8). However, the efficacy of SFβM or SF(EG)4OH in enhancing the 
action of tobramycin is not as good as colistin. The results showed the efficacy of two 
compounds in enhancing the action of colistin versus biofilms grown on a plastic surface, 
and modest enhancement of tobramycin (Figure 4.8). 
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Figure 4.7 Adjuvant compounds enhance the activity of antibiotics versus biofilms on an 
abiotic surface.  Shown is the impact of adjuvant compounds in combination with five 
antibiotics for a biofilm grown on an abiotic (polystyrene) surface.  
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Figure 4.8 Adjuvant compounds enhance the activity of antibiotics versus biofilms on an 
abiotic surface.  Shown is the impact of two different adjuvant compounds in 
combination with colistin (A) and tobramycin (B) for a biofilm grown on an abiotic 
(polystyrene) surface.  Addition of either compound markedly enhances the % killing (Y-
axis) of colistin.   
 
Our molecules enable tobramycin to eradicate the drug-tolerant bacteria and 
nascent persisters often generated by treatment with this antibiotic. Thus, we have 
discovered a class of adjuvant agents for controlling antibiotic-induced problems of 
tolerance, induced persisters, and potentially, fully-developed resistance.  To study drug 
tolerance and persister formation, we first grow a biofilm of PA strain PAO1 (a typical 
laboratory strain) on pegs224 with and without 0.3 µg/mL of tobramycin for 24 h to establish 
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an antibiotic-promoted biofilm, which contains both drug-tolerant bacteria and nascent 
induced persisters, and a native biofilm, respectively. For each biofilm, we then introduced 
a fresh medium containing a high concentration of tobramycin (50 µg/mL) with and 
without 40 µM of SFβM +/- 40 µM ABI. During this second culture period with a high 
dose of tobramycin, we evaluate the effect of our molecules on tobramycin’s killing of 
bacteria in biofilms as a function of time up to 24 h. Figure 4.9 shows that during the first 
10-h versus a control biofilm, our molecules have a small, non-significant impact on 
tobramycin-mediated killing; no such enhancement is observed beyond 10 hrs (Figure 
4.9.A). In contrast, for the tobramycin (0.3 µg/mL)-promoted biofilm,100 we make three 
observations (Figure 4.9.B). First, without our molecules, a slower rate of killing was 
observed from the 2nd hour to the 12th hour when this biofilm was treated with tobramycin 
(50 µg/mL; Figure 4.9.B, bracket labeled “a”). This result is consistent with the existence 
of tobramycin-tolerant bacteria. Second, our molecules (SFβM/ABI) enabled the high dose 
of tobramycin (50 µg/mL) to kill tolerant bacteria that developed during the first 24-h 
culture with low antibiotic concentration (Figure 4.9.B, bracket labeled “b”). Third, for 
both control (“native”) and tobramycin-induced biofilms, a plateau of killing was observed 
beyond ~12 h, but a higher resazurin dye signal (i.e., live bacteria)225-226 is observed for the 
biofilm without our molecules compared to with SFβM/ABI (Figure 4.9.B). We confirmed 
that at the end of the high dose tobramycin treatment (50 µg/mL), viable bacteria could be 
detected in both treatments (with and without our agents). This result indicates that the 
existence of persisters in both biofilms (but with different amounts) for the last 12-h of 
high dose tobramycin treatment. To further confirm that these bacteria were persisters, we 
collected large amount of these bacteria (from 20 pegs when plateaus were reached), 
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sonicated them in saline water (to prevent phenotype reversion), concentrated to get the 
pellet, and cultured the pellet again in LB containing 10 µg/mL of tobramycin, and in fresh 
LB. Whereas there was no growth observed in LB containing 10 µg/mL tobramycin, 
bacteria from this treatment always regrow in fresh medium. Together, these finding and 
data from Figure 4.9.B suggest that our molecules enable tobramycin to kill and/or to 
prevent a portion of persisters in the drug-treated bacterial population.     
 
 
                
Figure 4.9 The fluorescence of resazurin dye showing live PA strain PAO1 in (A) native 
and (B) tobramycin (Tob, 0.3 µg/mL)-promoted biofilms, which were treated with 50 
µg/mL Tob, and with (solid line) and without (dash line) 40 µM (~22 µg/mL) SFβM & 
40 µM ABI at different times. Interpretation of panel B: “a” consists of susceptible and 
tolerant bacteria, plus persisters; “b”, susceptible bacteria, plus persisters; “c”, 
tobramycin -induced persisters. 
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4.2.4. Adjuvant compounds enhance the efficacy of antibiotics to combat tobramycin-
tolerant subpopulations 
 
To study the effect of adjuvant compounds on the efficacy of antibiotics to 
combat tobramycin-tolerant subpopulations, we first grow biofilms of PAO1 on 
polystyrene chips with and without 0.3 µg/mL of tobramycin for 24 h to establish native 
and antibiotic-promoted biofilms. In the next 24 h, we increased the concentration of 
tobramycin to 50 µg/mL with and without 85 µM 3,5-DMDβM or 3,5-DMDβC, and then 
we monitored the development of live and dead subpopulations of P. aeruginosa biofilms 
by confocal image acquisition. A 488 nm laser line was used to visualize live cells within 
the biofilms formed by PAO1-EGFP strain. Dead cells within the biofilm stained by 
propidium iodide were visualized by 635 nm laser line. The image analysis program 
COMSTAT was used to analyze images stained with the LIVE/DEAD viability stain by 
recognizing the relative biomass that fluoresces green (live) and red (dead) at levels 
above a user-defined threshold value and reports the percentage of biomass that is alive 
and the percentage of biomass that is dead in each slice in a stack of images. The areas of 
the biomass fluorescing green and red represented the relative amounts of living and dead 
biomass in a biofilm. 
50 µg/mL tobramycin exposure to native biofilms led to a reduction in live cell 
biomass by ~50 %, and exposure to antibiotic-promoted biofilms led to a reduction in live 
cell biomass by ~40 % (Figure 4.10). We also examine the effect of the combination 
treatments with 85 µM 3,5-DMDβM or 3,5-DMDβC and tobramycin on native and 
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antibiotic-promoted biofilms. The results showed that the combination treatments lead to 
drastic change in live and dead cell subpopulation (Figure 4.10). 24 h of 50 µg/mL 
tobramycin exposure combined with 85 µM 3,5-DMDβM or 3,5-DMDβC to native 
biofilms caused live cell biomass further decreased by 50 % compared to when treated with 
50 µg/mL tobramycin alone (Figure 4.10). However, adding 85 µM 3,5-DMDβM or 3,5-
DMDβC in combine with 50 µg/mL tobramycin to the native biofilms caused a significant 
increase in dead cell biomass. There are 9 to 10 times more dead cells remained within the 
native biofilms after 24 h of 50 µg/mL tobramycin exposure combined with 85 µM 3,5-
DMDβM or 3,5-DMDβC compared to when treated with 50 µg/mL tobramycin alone 
(Figure 4.10). 
Similarly, the combination treatments with 85 µM 3,5-DMDβM or 3,5-DMDβC 
and tobramycin on antibiotic-promoted biofilms lead to drastic change in live and dead cell 
subpopulation as well (Figure 4.11).  24 h of 50 µg/mL tobramycin exposure combined 
with 85 µM 3,5-DMDβM or 3,5-DMDβC to antibiotic-promoted biofilms caused live cell 
biomass further decreased by 70 % compared to when treated with 50 µg/mL tobramycin 
alone (Figure 4.11). Dead cell biomass was significantly increased as well. There are 8 to 
12 times more dead cells remained within the antibiotic-promoted biofilms after 24 h of 50 
µg/mL tobramycin exposure combined with 85 µM 3,5-DMDβM or 3,5-DMDβC 
compared to when treated with 50 µg/mL tobramycin alone (Figure 4.11). 
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* 
Figure 4.10 Confocal microscopy images of 2-day old native biofilms. Biofilms attached 
to polystyrene chips were stained using the LIVE/DEAD biofilm viability stain (A). The 
images are Z-stack projections indicating the thickness of the biofilms for strain PAO1-
EGFP. Experiments were performed in triplicate, and a representative image for each 
condition is shown. Scale bar: 30 µm. The live and dead cell biomass of biofilm 
quantified using COMSTAT software (B). 
                                                 
* The work in this chapter is a collaboration with Felicia Burns in Luk group. She synthesized and 
characterized the two molecules, 3,5-DMDβM and 3,5-DMDβC, used in this chapter. 1HNMR and 
13CNMR collected by Felicia Burns were included for the purpose of completing the information. 
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* 
Figure 4.11 Confocal microscopy images of 2-day old antibiotic promoted biofilms. 
Biofilms attached to polystyrene chips were stained using the LIVE/DEAD biofilm 
viability stain(A). The images are Z-stack projections indicating the thickness of the 
biofilms for strain PAO1-EGFP. Experiments were performed in triplicate, and a 
representative image for each condition is shown. Scale bar: 30 µm. The live and dead 
cell biomass of biofilm quantified using COMSTAT software (B). 
                                                 
* The work in this chapter is a collaboration with Felicia Burns in Luk group. She synthesized and 
characterized the two molecules, 3,5-DMDβM and 3,5-DMDβC, used in this chapter. 1HNMR and 
13CNMR collected by Felicia Burns were included for the purpose of completing the information. 
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4.3. Conclusion 
In this chapter, we confirmed that our molecule, SFβM, inhibited both tobramycin-
promoted biofilm formation and swarming motility, and thus SFβM overcomes the impact 
of tobramycin at controlling these two activities. 3,5-DMDβM and 3,5-DMDβC showed a 
similar effect on inhibiting both tobramycin-promoted biofilm formation and swarming 
motility. Thus, we can conclude that disaccharide molecules having branched 
hydrocarbons inhibit tobramycin-promoted bacterial activities. SFβM and SF(EG)4OH 
enhanced the bactericidal action of antibiotics colistin and tobramycin on biofilms grown 
on a polystyrene surface. In addition, SFβM/ABI enabled tobramycin to kill and to prevent 
a portion of persisters in the drug-treated bacterial population.  Confocal microscopy study 
revealed that our synthetic molecules, 3,5-DMDβM and 3,5-DMDβC, can act as adjuvant 
compounds to enhance the efficacy of antibiotics to combat tobramycin-tolerant 
subpopulations. Thus, supplementing conventional antibiotic treatment with an adjuvant 
compound seems to be a promising therapy for eradicating biofilm-associated infections. 
Furthermore, our study showed that co-treatment of adjuvant compounds along with 
antibiotics is important to kill antibiotic-tolerant cells and prevent new persisters to form. 
It highlighted the importance of developing motility inhibitors that can be given to 
chronically infected patients, with the aim of constituting functional anti-biofilm 
chemotherapies.  
 
4.4. Materials and Methods 
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4.4.1. Stock solutions  
 
Stock solutions of all the agents were prepared in autoclaved water, sterilized by 
filtering through a 0.2 µm syringe filter, and stored at -20 °C in sealed vials. An 
appropriate amount of sterile water was added to controls in all assays to eliminate the 
solvent effect. 
4.4.2. Bacterial strains     
 
Wild-type P. aeruginosa PAO1 and PAO1-EGFP strains were obtained from Dr. 
Guirong Wang (Upstate Medical University, Syracuse). library (PAO1 transposon mutant 
library).156 
 
 
4.4.3. Confocal laser scanning microscopy (CLSM)     
 
Biofilms were grown by inoculating the bacteria on polystyrene coupons (3/8 in. 
× 3/8 in.) with or without agents in a 24-well microtiter plate. The saran-wrapped plate 
was then incubated at 37 oC under 100 rpm shaking condition for 24 h. Inhibition of 
biofilm formation was directly observed. Eradication of preformed biofilm was 
performed after bacterial cultures were gently pipetted out and wells were washed, and 
fresh media was added containing predetermined concentrations of antibiotics and 
synthetic agents for another 24 h. Each polystyrene coupon was then washed gently by 
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dipping into 0.85 w/v% aqueous NaCl solutions twice and then placed on a microscope 
cover glass (50 x 24mm, No. 2, Fisher Scientific, Pittsburgh, PA). The biofilms were 
visualized using a Zeiss LSM 710 Confocal Laser Scanning Microscope (Carl Zeiss, 
Jena, Germany).  
 
4.4.4. Swarming assay  
 
Swarm agar plates were made using M8 medium supplemented with 0.2% 
glucose, 0.5% casamino acid, 1 mM MgSO4 and solidified with 0.5 % Bacto agar. 
Bacterial culture with OD600 between 0.4 to 0.6 was inoculated as 3 μl aliquots. Swarm 
agar plates were incubated at 37 °C for 12 h and then incubated for an additional 12 h at 
rt. For each set of the experiment, all the swarm plates were poured from the same batch 
of agar and allowed to dry for 1 h before inoculation of bacteria.  
 
4.4.5. Resazurin cell viability assay 
 
On multi-array pegs, biofilms were grown for 24 h without and with 0.3 µg/mL 
tobramycin to form control and tobramycin -promoted biofilms, respectively. The 
medium was replaced with fresh medium supplemented with 50 µg/mL tobramycin, and 
without or with 40 µM SFβM & 40 µM 2-ABI and cultured for the times indicated. The 
biofilms were sonicated (15 min at 30 kHz). Resazurin was added to the sonicated 
culture, followed by quantifying the fluorescence at 590 nm. 
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1H NMR spectra* 
  
                                                 
* This spectrum is collected by Felicia Burns. 
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13C NMR Spectra* 
 
                                                 
* This spectrum is collected by Felicia Burns. 
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Chapter 5 Selective Binding of Synthetic Disaccharide Derivatives to LecA Revealed 
by Fluorescent Polarization* 
5.1. Introduction  
5.1.1. Background of Fluorescence polarization 
Fluorescence polarization (FP) is a powerful method for probing protein-ligand 
interactions, that involve the interaction of small fluorescent ligands with large 
receptors.227-228 In 1926, Francis Perrin first described the theoretical basis of fluorescence 
polarization.229  In the 1950s, Gregorio Weber extended Perrin’s theoretical work and 
developed the first instrumentation to measure fluorescence polarization, and applied it to 
study the interactions between dansyl chloride and bovine serum albumin.230-232  Since then, 
the principles of fluorescence polarization have been applied extensively in assays to 
enable high-throughput screening of small molecule libraries for the purposes of probe 
development and drug discovery.233-236 Fluorescence polarization assay is based on the 
rotational differences between the depolarization of the emitted light before and after the 
interaction of molecules.237 A small fluorophore rotates in random directions, resulting in 
rapid depolarization of light, while a larger complex molecule rotates slower and depolarize 
light at a reduced rate. The difference in depolarization rate can be measured by 
fluorescence spectrometer. Specifically, the small fluorophore in solution is first excited 
by a linearly polarized light. The parallel and perpendicularly polarized components of the 
fluorescence emissions are measured. If the fluorophore is unbound, the polarization 
                                                 
* While I conducted all the experiments in this work, the idea of using fluorescent polarization to detect 
LecA binding to out molecules is initiated by Pankaj Patil, and he contributed substantially to the design of 
the experiments.  
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anisotropy value remains at a relatively low level. If it is bound to a larger receptor, its 
rotation is slowed, and the polarization anisotropy increases. In competition binding FP 
assays, the presence of unlabeled ligands or small molecule inhibitors of the interaction 
results in the displacement of the labeled fluorescent ligands, which increases the tumbling 
motion of the free fluorescent ligands in the solution, and a decrease in FP value can be 
detected.238 It has been widely used in numerous studies to measure the binding affinity 
(IC50 or Kd measurement) of various receptors with their respective ligands.
239-241 
Fluorescence polarization assay is a homogeneous assay which can perform very quickly 
since it does not require removal of unreacted reagents. Fluorescence polarization has 
emerged as a technique which allows for high throughput and in situ detection of the 
potency of a given competitive inhibitor.237, 242-243 
 
5.1.2. Lectin protein of bacteria 
 
Lectins are proteins that can bind specific carbohydrate structures which play 
important roles in interactions and communication between bacterial, mammalian, plant or 
fungi cells typically for recognition of glycan epitopes in multivalent carbohydrates and 
glycoprotein receptors.244-245 Owing to carbohydrate binding specificity of lectins, they 
have a huge impact on cell adhesion and host cell cytotoxicity, thus play a crucial role in 
the pathogenic property of the parasite.246-248 In the case of P. aeruginosa, the bacteria 
produce two lectins termed LecA (PA-IL) and LecB (PA-IIL).249-250 These lectins appear 
to function in multistep adhesion events which involves proteolysis and elastolysis to be 
cloned and sequenced as well as cytotoxins for respiratory epithelial cells.251-253 Galactose-
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specific LecA is a tetrameric protein consisting of four 12.75-kDa subunits.249, 254 LecB is 
about 12 ~13 kDa and exhibits a high specificity for fucose.250, 255 LecA and LecB have 
both been shown to interact with the glycosphingolipid antigens, which is a huge factor for 
the infectivity and pathogenicity of P. aeruginosa.256-257 The crystal structures of both 
lectins show homotetrameric assemblies and calcium ions mediating the recognition of 
their carbohydrate ligands.257-259 LecA has an intermediate affinity for its monovalent d-
galactose-derived ligands in the Kd = 50–100 μM range and Phenyl -d-galactosides and 
derivatives at approximately 10 μM.259-260 Recent studies revealed the affinities for LecA 
in the nanomolar range based on divalent galactoside compounds.260-261 Here, we reveal the 
selective binding of maltose and cellobiose derivatives to the bacterial LecA by a 
fluorescence polarization-based assay.  
 
5.1.3. The aim of the chapter 
In this chapter, we designed and synthesized fluorescent-tag labeled ligand, βGal-
aryl-Dansyl, for LecA protein. We examined the ligand-receptor binding between βGal-
aryl-Dansyl and LecA by a fluorescence polarization-based assay and evaluated potential 
ligands for LecA by competitive fluorescence polarization assay.  
 
5.2. Results and discussion 
 
5.2.1. Design of fluorescent-tag labeled ligand for LecA protein  
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 The fluorescent polarization has been developed and used to detect binding between 
LecA and two phenyl-linked reporter ligands by Alexander Titz and coworkers.259 In their 
work, they synthesize two fluorescent molecules (See Figure 5.1).  
 
Figure 5.1 Structures of fluorophore-tagged phenyl glycosides for LecA ligands. The 
listed dissociation constants are published in the literature.259 
We design an efficient one-step synthesis of a fluorescently labeled ligand that 
would also bind to LecA. This molecule will be used to establish a fluorescence 
polarization assay with LecA. We explore this new structure because of the efficiency of 
the synthesis (72 % yield).  The ligand βGal-aryl-Dansyl is a D-Galactose-based probe 
tethered with a dansyl group as the fluorescent part.  
 
 
 
 
(K
d
 = 19.2 ± 4.8 μM) (Kd =  8.1 ± 2.1 μM) 
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Scheme 5.1 New Fluorescent Ligand Molecule, βGal-aryl-Dansyl, for LecA – Efficient 
One-Step Synthesis 
 
5.2.2. βGal-aryl-Dansyl binds to LecA with a Kd of 10.7 ± 0.8 μM, based on by 
fluorescence polarization  
 
To evaluate the binding of βGal-aryl-Dansyl to LecA, a direct titration with 
increased amounts of LecA was performed along with increased amounts of BSA as a 
negative control. The ligand showed a dose-dependent increase in fluorescence 
polarization with increasing concentration of LecA, while did not show any significant 
effect on BSA (Figure 5.2). Kd value was obtained from a four-parameter fitting procedure 
to the dose-dependent increase in fluorescence polarization by using Origin software. The 
fitting equation is y = A1 + (A2-A1)/(1 + 10^((LOGx0-x)*p)), and A1 and A2 correspond 
to bottom and top asymptotes, p is the hill slope and LOGx0 is the center value when 
y=(A1+A1)/2. The model showed the fitted curve equation is: y=(0.12213-0.07179)/(1 + 
10^((10.17-x)*0.052)), and the R2=0.97. The calculated Kd of the binding of βGal-aryl-
Dansyl to LecA is 10.17 ± 1.71 μM based on the direct binding curve derived from 
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fluorescence polarization assay, which is consistent with the reported Kd values of phenyl-
β-galactoside derived ligands (Kd = 7.4 μM and 8.1 μM) in the low μM range.18 
 
 
Figure 5.2 Direct Titration of βGal-aryl-Dansyl (200 nM) with Increasing [LecA] 
Revealed Kd of 10.17 ± 1.71μM. Dissociation constants were obtained from a four-
parameter fitting procedure to the dose-dependent increase in fluorescence polarization.  
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5.2.3. The half maximal inhibitory concentrations (IC50) of synthetic molecules against 
βGal-aryl-Dansyl are between 10-20 µM 
 
The half maximal inhibitory concentration (IC50) of our synthetic molecules against 
βGal-aryl-Dansyl were determined by competitive binding assay using FP. The basic 
principle of the assay is shown in the Figure 5.3.A. Basically, in a competition binding FP 
assays, the presence of unlabeled ligands or small molecule inhibitors of the interaction 
results in the displacement of the labeled fluorescent ligands, which increases the tumbling 
motion of the free fluorescent ligands in the solution, and a decrease in FP value can be 
detected. The results revealed that IC50 of SFβM and SFβC are both at ~15 μM, and DβM 
has an IC50 of ~19 μM. However, SFEG4OH and rhamnolipids did not show any binding 
ability toward LecA (Figure 5.3.B). 
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Figure 5.3 Competitive binding assay principle for monitoring LecA-ligand interaction 
using fluorescence polarization (A). Fluorescent polarization reading of solutions of 
LecA (final concentration: 20 µM) and βGal-aryl-Dansyl (200 nM) in 0.1M Tris-HCl pH 
Fluorescently tagged ligand 
high FP LecA 
Competitive ligand 
low FP 
A 
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7.5 and 6 μM CaCl2 with serial dilutions (0.1 μM to 100 μM) of test compounds, SFβM, 
SFβC, DβM and SFEG4OH (B). IC50 was obtained from a four-parameter variable slope 
model. 
5.3. Conclusion 
To conclude, we have used fluorescent polarization assay to show a fluorophore-
derivatized disaccharide can bind to LecA. We also showed that our potent molecules can 
displace this fluorophore disaccharide from LecA, causing a decrease in fluorescence 
polarization. Together these results in chapter 6 suggest that SFβM is a chimeric ligand 
that binds to two different targets, LecA101-102, and pili,262 and also explains why two 
distinct processes (biofilm formation and swarming) are inhibited by the same molecule.  
 
5.4. Materials and Methods  
5.4.1. Synthesis of βGal-aryl-Dansyl  
 
4-Aminophenyl β-D-galactopyranoside(0.12 g, 1.2 mmol) in anhydrous DMF (2 
mL) was added to Et3N (0.53 g, 0.53 mmol) in anhydrous DMF (5mL) at 0 ºC. To this 
solution was added dansyl chloride (0.41 g, 1.5 mmol). After stirring at 0 ºC for 2 hr, the 
mixture was concentrated, and the residue obtained was subjected to the purification by 
column chromatography to yield a yellow solid product (0.44 g, 72 %). 1H NMR 
(400MHz, CDCl3): δ 8.47 (d, 1 H, dansyl), 8.24 (d, 1 H, dansyl), 8.20 (d, 1 H, dansyl), 
7.65-7.69 (m, 2 H, dansyl), 7.39 (d, 1 H, dansyl), , 6.92–6.81 (m, 4H, ArH), 4.75 (d, J = 
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7.7 Hz, 1H), 4.37 (s, 2H, CH̲2NHR), 3.69 (d, J = 3.1 Hz, 1H), 3.58–3.46 (m, 5H), 2.84 (s, 
6H,-CH3). 
 
 
5.4.2. Direct binding of fluorescent ligands to LecA  
 
The fluorescent ligands were dissolved in DMSO to a final concentration of 3 mg 
mL−1. 2 mg LecA was dissolved in 1 mL of 0.1M Tris-HCl pH 7.5 and 6 μM CaCl2. A 
serial dilution of LecA samples was prepared. The solution of one fluorescent ligand was 
added to a final concentration (final concentrations of βGal-aryl-Dansyl: 200 nM). After 
incubation for 1 h at r.t., fluorescence polarization was determined using Edinburgh 
FLS9801 Spectrometer. During measurement, the samples were illuminated with vertically 
polarized light at 330 nm (for βGal-aryl-Dansyl), and vertical and horizontal fluorescence 
components were measured, and the fluorescence polarization values were calculated 
subsequently.  
 
5.4.3. Competitive binding assays   
 
Typically, to a solution of LecA (final concentration: 20 µM) and fluorescent 
ligand (final concentrations of βGal-aryl-Dansyl: 200 nM; FITC-EG12-SF: 20 nM) in 
0.1M Tris-HCl pH 7.5 and 6 μM CaCl2, serial dilutions (0.1 μM to 100 μM) of test 
compounds (SFβM, SFβC, DβM, SFEG4OH) were added. After the addition of the 
reagents, the samples were incubated for 4–6 h at r.t. fluorescence polarization was 
determined using Edinburgh FLS9801 Spectrometer. During measurement, the samples 
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were illuminated with vertically polarized light at 330 nm (for βGal-aryl-Dansyl) and 490 
nm (for FITC tagged fluorophore), and vertical and horizontal fluorescence components 
were measured, and the fluorescence polarization values were calculated subsequently.  
 
1H NMR spectra 
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Chapter 6 Pili-mediated Signaling Hypothesis and Validation. 
6.1. Introduction  
6.1.1. The attempt of using Pili as the vaccine target  
 
Gram-negative bacterial surfaces have type IV pili, which can evoke the host 
immune response and are potential drug and vaccine targets.263 Type IV pili are the 
assembly of pilin subunits, which generates a polymeric “machinery” that can mediate 
various cellular functions, including cell signaling, surface motility, microcolony, and 
biofilm formation, host-cell adhesion.264-265 It has been reported that for many Gram-
negative pathogens, disruption of pilus assembly can result in severely reduced 
virulence.266-268 The Pseudomonas aeruginosa PAK pilin D-region is undergoing active 
investigation as a vaccine target because anti-D-region antibodies could potentially block 
the binding of a broad range of P. aeruginosa strains to the host-cell receptors.269 
However, despite high numbers of patients who may develop P. aeruginosa infections 
and the threat of antibiotic treatment failure due to bacterial resistance, there is 
surprisingly no P. aeruginosa vaccine currently available on the market, although many 
attempts have been made in the past, most of the published studies are preclinical, some 
describe results from phases I and II studies and only two vaccines have made it phase III 
studies in CF patients.270-271 
 
6.1.2. Exploring bulky aliphatic chain of disaccharide derivatives for controlling 
bacterial multicellular activities 
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Based on the results from previous lab members in Luk’s group, among different 
DSD, saturated farnesol disaccharide compound, like SFβM, has the highest anti-biofilm 
ability.98-99 This observation leads us to explore even bulkier tail group to be attached on 
disaccharide, which might increase anti-biofilm ability even more. A well-defined 
binding pocket can bury the recognized ligands and exclude other molecules. The 
conformation of the binding pocket might match well for the bulky tail compounds. 
Furthermore, bulky tail DSD is relatively more difficult to assemble than non-bulky tail 
DSD, because bulky hydrophobic tail DSD is more difficult to satisfy the 
molecular packing requirements for forming a micelle than the non-bulky tail DSD. Since 
bulky tail DSD is hard to form a micelle, it is more likely to move around in a free 
molecule form. Hence, it has a higher chance to bind to the binding pocket (Figure 6.1). 
 
 
Figure 6.1 Representation of the hypothesis that bulky hydrophobic tail surfactant is more 
difficult to satisfy the molecular packing requirements for forming a micelle than the 
non-bulky tail surfactant.  
Cholestanol is a neutral lipid that plays an essential role in the maintenance of the 
integrity of biologic membranes and serves as a precursor in the synthesis of many 
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endocrine mediators.272 Recent clinical has demonstrated a possible linkage of 
cholestanol to prostatic cancer and benign prostatic hyperplasia.273-275 Shinji and his 
coworker have found that chemically synthesized sugar-cholestanol compounds showed 
strong inhibiting activity against the proliferation of colorectal and gastric cancer cells.276 
In recent work, chemically synthesized sugar-cholestanols were demonstrated to possess 
potential multi-target anticancer activity against human esophageal cell lines because 
they induced apoptotic cell death of esophageal cancer cells.277 Based on the past study 
led by Gauri and Nischal in Luk group, a bulky aliphatic chain of disaccharide 
derivatives, like SFβM, have the high anti-adhesion, and anti-biofilm formation and 
dispersion activity.98, 149 We believe that bulky aliphatic chain that may cause higher 
potency than saturated farnesol at enabling disaccharide derivatives on controlling 
bacterial activity. We also speculate that inducing rigidity, multi-ring structures help limit 
conformation space, which might further increase the potency for disaccharide 
derivatives on controlling bacterial activity. 
 
6.1.3. Covalent Ligation Strategy for Searching Pili Binding Sites 
 
Covalent ligation has emerged as a valuable tool for the development of modified 
proteins and the study of binding activities since the techniques that allows covalent 
ligation have been developed over the last few decades.278-280 The complementary use of 
both genetic and chemical methods has provided a large toolbox that allows us to 
immobilize, cross-link or tag proteins or even alter protein properties.281 Covalent 
ligation is highly specific and appending various probes to these ligands is synthetically 
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straightforward and often does not reduce binding affinity for the protein targets since 
nature also uses a covalent modification of proteins to modulate their function which 
originated from millions of years of evolution, have adapted their structure for covalent 
binding to proteins.282-283 The most straightforward method to covalently attach a small 
molecule to a protein sequence is to use a binding interaction. For example, Nolan and 
coworkers explored a fluorescein–SLF0 conjugate which was used to label several 
FKBP12(F36V) fusion proteins in NIH3T3 and COS-7.284 Farinas and Verkman used 
antibody tags fused to localization signal sequences to target various hapten– fluorophore 
conjugates to specific subcellular compartments in live cells.285 One approach is to 
engineer a mildly reactive functional group on the ligand molecule such that the ligand 
does not lose its binding activity to its receptor protein, and upon binding, the mildly 
reactive functional group will react covalently with a specific amino acid on the active 
binding site of the receptor. A few such mildly reactive functional groups are known to 
carry this binding enabled covalent conjugation. Chen and coworkers have surveyed a 
range of affinity probes for protein labeling.286 Our initial design matches with their 
finding that epoxy has great potential for protein modification yield and efficiency. 
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Figure 6.2 Schematic Representation Covalent Ligation upon Binding between Ligand 
and Receptor 
 
6.1.4. Transmission electron microscopy of Surface Destructed Bacteria  
 
The development of the transmission electron microscope (TEM), has increased 
the resolution limit over one thousand times greater than the conventional light 
microscope, which helped revolutionize many aspects of microbiology.287 In general, a 
TEM system includes a fine electron beam, created by a high-voltage, electric current-
heated tungsten filament, focused by magnetic lenses. The electron beam passes through 
an ultrathin plastic section, which impedes the beam in proportion to their respective 
degrees of electron density. The differential transmission of the electrons creates an 
image that is captured on a fluorescent screen. The first functional transmission electron 
microscope was developed in the early 1930s by Ruska who constructed an electron 
microscope with three magnetic lenses, condenser, objective, and projector.288 After 
scientists fully developed new methods for preparation and new procedures for fixation, 
embedding, sectioning, and staining,289-293 TEM has been used as a strong research tool in 
microbiology for high-resolution structural studies of bacteria and their appendages.294 
TEM technique also allowed significant advances in the understanding of infection 
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mechanisms, antibiotic tolerance, and biofilm geochemistry.295-297 TEM has the 
advantage over scanning electron microscope (SEM), since a drastic preparation protocol 
of SEM sample preparation may eliminate appendages.298 The TEM technique is widely 
used to study the morphology of bacterial cells and their surface structures, such as 
flagella and pili.299-302  
 
6.1.5. Membrane Protein Study 
 
Understanding of the properties of membranes is vital in many aspects of biology 
since membrane plays important roles in the functioning of cells such as organizing the 
shape of the organelles and the cells, the transport of ions, metabolites, and proteins 
across plasma membranes, and RNA transport across nuclear membrane.303-305 Recently, 
the complete genome sequencing estimated the transmembrane proteins represent over 30 
% of total proteins.306-307 To understand how membrane proteins work and to generate 
drugs that target specific sites within the protein, it is important to purify the protein to 
fully characterize it. However, membrane proteins are difficult to purify for the following 
reasons. First, most membrane proteins are present at low levels; and second, they are 
embedded in the lipid bilayer and require detergents to become soluble in aqueous 
systems.308 Large proteins whose molecular weight is above 250 kDa can be easily 
separated as their individual subunits using simple centrifugation, while very small 
proteins require special buffer systems in the second dimension to resolve proteins with 
apparent masses less than 8 kDa.309 Hydrophobic proteins which include the key cell-
surface proteins, many of which are assumed to play important roles in cell adhesion, cell 
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recognition, and cell differentiation require special systems such as extraction by using 
urea, CHAPS, DTT, and alkaline buffers or sucrose density gradient centrifugation.309-312 
Among them, alkaline extraction has gained widespread popularity as an easy and 
efficient method for selectively stripping extrinsic proteins off membranes without 
affecting the disposition of integral components.312 
 
6.1.6. The aim of the chapter 
 
In this chapter, we explored the effect of ChC3βM on these biological activities 
by P. aeruginosa. In addition, to search the hypothetical receptor to gain insight into the 
mechanism of ligand-receptor interactions, we also synthesized TEGβM and TGMEβM 
to test their effect on biological activities by P. aeruginosa. To study the potential 
interaction between our molecules and pili proteins, we designed and synthesized active 
agents containing a functional group that can react with an amine group, which can 
covalently and permanently attach to the receptor protein only when the physical ligand-
receptor binding takes place. In addition, we also tested the effect of externally added pili 
on the swarming motility of P. aeruginosa to support the mechanistic study of the pili as 
the receptor (or one of the receptors) that will bind to rhamnolipids and our synthetic 
agents, and upon binding, causing the bacterial activities. Furthermore, to study the effect 
of our synthetic agents on the morphology of bacterial surfaces we have imaged bacterial 
surfaces using a transmission electron microscope. In addition, we studied the membrane 
protein composition using an alkaline buffer extraction method and then visualized by the 
SDS-PAGE gel. 
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6.2. Results and discussion  
 
6.2.1. Cholestanol-sugar compound has activity at relatively low concentration but with 
low potency 
 
Quantification of PAO1 biofilm was done by crystal violet (CV) dye-based assay 
after 24h of inoculation with and without maltose derivatives. We found that synthesized 
ChC3βM exhibited biofilm inhibition activity against P. aeruginosa. At 10~20 µM 
concentration, ChC3βM showed 60% biofilm inhibition. However, when the 
concentration is higher, the biofilm inhibition rate decreased to 30%. Surprisingly, when 
the concentration is reduced to nM level, ChC3βM still showed 20~30% biofilm 
inhibition (Fig. 6.3). 
If we assume that an optical density (OD) reading of 1 corresponds to 109 bacteria 
per ml. This value is true for E. coli. Because E. coli and P. aeruginosa are similar in 
shape and dimension, we adopted this value for our estimation. Thus, as OD=1 
corresponds to 109 bacteria/ml, there are 2*107 bacteria in a well containing 200 µL 
solution when OD=0.1. After 24 h incubation, the OD is approximately 1, which 
corresponds to 2*108 bacteria in 200 µL. For the ChC3βM molecules, there are 
1.2*1014 molecules in 200 µL of a 1 µM-solution. So even the concentration is reduced to 
1 nM, the molecule number, 1.2*1011, is still about 1000-fold higher than bacteria 
number (2*108). Thus, if we can reach IC50 at nM level, it would a significant 
improvement for anti-biofilm drug development.  
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Figure 6.3 Inhibition of biofilm by ChC3βM at different concentrations on PAO1 
measured by CV dye assay. The compound showed biofilm inhibition activity at 
relatively low concentration but with low potency. 
 
6.2.2. Disaccharide oligo-ethylene glycol has an insignificant effect on bacteria 
 
For synthesized DSD, TEGβM and TGMEβM, we tested their effect on swarming 
motilities of PAO1 and rhlA on agar plates. According to the result of swarming assay, 
TEGβM and TGMEβM have no effect on swarming motilities of both PAO1 and rhlA 
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(Figure 6.4 and Figure 6.5). The steric and electronic structure of the aliphatic tail is 
concluded to have great importance on the ability of these compounds to control bacterial 
activities. In addition, C6OC5-β–Cellobiose, and C3OC8-β–Cellobiose have an 
insignificant effect on the activities of P. aeruginosa (See chapter 3). Those results lead us 
to hypothesize that there is a ligand-receptor mechanism involved with these signaling 
molecules. The structure of the aliphatic side chain is important in the binding of these 
compounds to the receptor, explaining why the introduction of a single ether linkage 
obliterates the potency of our compounds since binding sites are often highly sensitive to 
the molecular details of its ligands. 
 
 
 
 
 
 
Figure 6.4 Images of swarming motilities of PAO1 and rhlA on agar plates containing 
different concentrations of TEGβM. The compound does not promote swarming of rhlA 
or promote tendril formation in PAO1. 
rhlA 
PAO1 
No agent 85 µM DβM 5 µM      15 µM      30 µM     85 µM    170 µM   
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Figure 6.5 Images of swarming motilities of PAO1 and rhlA on agar plates containing 
different concentrations of TGMEβM. The compound does not promote swarming of 
rhlA or promote tendril formation in PAO1. 
 
6.2.3. The specific covalent ligating agent can bind to pilin, but not other proteins 
  
 PA1244 is a wild-type clinically isolated strain of Pseudomonas aeruginosa, 
which is hyper-piliated.313 P. aeruginosa strain 1244N3 is a mutant of PA1244 that is 
unable to produce pilin due to an inactivated rpoN gene.314 When inserted with plasmid 
pPAC46, PA1244N3 could produce glycosylated pilin. Plasmid pPAC46 contains the 
strain 1244 pilA and pilO genes under the control of a tac promoter. We successfully 
purified a large amount of pili proteins using a P. aeruginosa PA1244N3/pPAC46 strain. 
5 µM     15 µM      30 µM     85 µM    170 µM 
rhlA 
PAO1 
No agent 85 µM DβM 
TGMEβM 
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Based on the preliminary results of MALDI-MS experiment, we have confirmed that pili 
can be covalently modified by our agent available of covalent ligation, while other 
proteins, like BSA and lysozyme, were not covalently modified by the same agent. 
(Figure 6.6) In addition, among SF(EG)n-epoxy (n=3, 4, 5), SF(EG)4-epoxy has the 
highest yield for covalent ligation with Pili protein (Figure 6.7). 
 
Figure 6.6 SDS-PAGE gel image of purified pili protein and the MALDI-MS results. 
Expressed Pili Protein from PA1244N3(pPAC46) Matches the Reported Mass of 
16,307±25 (ref: James G. Smedley, Erica Jewell, Jennifer Roguskie, Joseph Horzempa, 
Andrew Syboldt, Donna Beer Stolz, and Peter Castric,* Influence of pilin glycosylation 
on Pseudomonas aeruginosa 1244 pilus function[J]. Infection and immunity, 2005, 
73(12): 7922-7931.) 
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Figure 6.7 MALDI-MS Result Indicates Pili is Covalently Modified by SF(EG)4-epoxy 
(MW=459) in PBS (pH 8.2). Among SF(EG)n-epoxy (n=3, 4, 5), SF(EG)4-epoxy has the 
highest yield for covalent ligation with Pili protein. 
 
6.2.4. Supporting evidence of ligand-receptor binding between DSD and pili protein by 
swarming assay 
 
To support that pili could be the receptor that binds to rhamnolipids, and our 
synthetic agents, we conducted an experiment where pili protein was applied on the 
surface of the soft agar gel used for observing the swarming motility of wild-type P. 
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aeruginosa, PAO1. If swarming is initiated by ligand-receptor binding between 
rhamnolipids (or our molecules) and pili protein on the bacterium surfaces, then the 
presence of pili proteins on the agar gel (outside the bacteria) will sequester the natural 
molecules (rhamnolipids) secreted by the bacteria, and thus inhibit the bacteria’s 
swarming motility. If bacterial swarming is a physical effect, the presence of pili protein 
will unlikely not reduce the swarming motilities. Controls of other proteins (BSA) were 
used to observe any nonspecific effect due to the presence of proteins on the gel. The 
results indicate that pili protein inhibits swarming motility of PAO1, while BSA does not 
inhibit the swarming motility of PAO1. (See Figure 6.8) 
 
 
 
 
 
 
Figure 6.8 Pili protein inhibits swarming motility of PAO1 while BSA does not. After the 
agar was cooled to r. t. and solidified, 1 mL of the corresponding solution was evenly 
spread on the surface and dried for 1 h. Then 3 µL of the PAO1 culture (OD = 0.4 - 0.6) 
was spotted on the center. Pictures were taken after the plates were put in 37 ℃ 
incubators for 12 h and then 22℃ for another 12 h. 
 
PAO1 
1.0 mg/mL Pili 
(half surface)   
0.5 mg/mL 
BSA 
0.5 mg/mL Pili Control 
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Previous lab member Gauri in Luk lab has examined the effect of a class of 
synthetic analogs of rhamnolipids at controlling (promoting and inhibiting) the swarming 
motility of a non-rhamnolipid-producing strain – rhlA – of P. aeruginosa. When the 
swarming gel was supplemented with 85 uM DβM, the non-swarming PA strain rhlA will 
swarm on the agar gel plate. Here we tested the effect of added pili protein on Swarming 
Motility of rhlA in the Presence of 85 µM DβM. The results showed that the externally 
added pili protein significantly reduced the swarm area of rhlA in the presence of 85 µM 
DβM (Figure 6.9). In contrast, externally added BSA protein did not show any significant 
inhibition on the swarming motility of rhlA in the presence of 85 µM DβM (Figure 6.9). 
Those results support our proposed mechanism of ligand-receptor binding between 
rhamnolipids (or our molecules) and pili protein. 
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Figure 6.9 Pili protein inhibits swarming motility of rhlA in the presence of 85 µM DβM 
while BSA does not. Predetermined concentrations of agents were added when preparing 
the swarming agar plates. After the agar was cooled to r. t. and solidified, 1 mL of the 
corresponding solution was evenly spread on the surface and dried for 1 h. Then 3 µL of 
the rhlA culture (OD = 0.4 - 0.6) was spotted on the center. Pictures were taken after the 
plates were put in 37 ℃ incubators for 12 h and then 22℃ for another 12 h. 
However, there is another possibility that the externally added pili can act as a pili 
inhibitor which can inhibit swarming motility by pili-pili interaction.  To rule out such an 
alternative mechanism of inhibition effect, we proposed another experiment to confirm 
whether ligand-Pili interaction or pili-pili interaction is dominating in the inhibition effect 
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of externally added pili protein (Figure 6.10). Predetermined concentrations of SFβM 
were added in the swarming agar plates. Then 1 mL of 1.0 mg/mL of pili solutions were 
spread on the agar plate and dried for 1 h. Controls of other proteins (BSA) were used to 
observe any nonspecific effect due to the presence of proteins on the gel. PAO1 bacteria 
were inoculated on the agar plates followed by 12 h incubation under 37 C and then 
another 12 h under r.t. At 15 µM, SFβM inhibits swarming motility of PAO1. However, 
under the same condition plus the externally added pili, the swarming inhibition effect of 
SFβM was neutralized and the swarming pattern showed up again. Although the 
swarming area of the re-promoted PAO1 is not as pronounced as the no agent control of 
PAO1 swarming, the swarming re-promotion effect is still evident (Figure 6.11). The 
results confirmed that pili protein inhibits swarming motility of PAO1 by ligand-Pili 
interaction instead of pili-pili interaction.  
 
Figure 6.10 Mechanism hypothesis: ligand-pili interaction or pili-pili interaction? 
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Figure 6.11 Add swarm-inhibitor (SFβM) with pili in gel cause re-promotion of 
swarming motility of PAO1. Predetermined concentrations of agents were added when 
preparing the swarming agar plates. After the agar was cooled to r. t. and solidified, 1 mL 
of the corresponding solution was evenly spread on the surface and dried for 1 h. Then 3 
µL of the PAO1 culture (OD = 0.4 - 0.6) was spotted on the center. Pictures were taken 
after the plates were put in 37 ℃ incubators for 12 h and then 22℃ for another 12 h. 
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6.2.5. Bulky DSDs Like SRβM and rhamnolipids Modulate PA14 Swarming while other 
potent agents that can control PAO1 and rhlA swarming have weak effects 
 
PA14 always exhibit tendril formation when they swarm on a soft agar gel, 
whereas PAO1 swarm evenly outward radially, resulting in a circle pattern. There are 
currently no reported chemicals that control the swarming of PA14. However, we did 
find that natural product rhamnolipids inhibit the swarming of PA14 starting at around 60 
µM (Figure 6.12). Surprisingly, the potent agents that can modulate the swarming 
motilities of PAO1, like DβM and BPDeβM, did not show any control of the swarming 
motility of PA14. However, SRβM modulated the swarming motility of PA14. For this 
molecule, swarming motility of PA14 was inhibited at relatively low concentration, 10 
µM, but reactivated again as the concentration was increased. The swarming motility 
reached a second maximum at 60 µM and then started to decrease again. A second 
inhibition was observed at 170 µM. These results indicate that while pili structures vary 
between different mutants and different strains. Such an oscillation effect of chemicals on 
biological activities was described by Eberhard150 and coworkers for quorum sensing 
molecules for Photobacterium fischeri. This oscillation in swarming pattern activity due 
to the difference in chemical concentration is symbolic of an oscillatory response by the 
bacteria to the chemical stimuli.151  
Oscillations are ubiquitous in nature and occur in physical, chemical and 
biological systems that are periodically repeating variations of some measure or quantity 
about a central value or between two or more different states.151 At the cellular level, an 
oscillating system consists of three parts: the oscillator, which generates the oscillatory 
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output; the input pathways that regulates the oscillator in response to external or internal 
signals; and output pathways that couple information about the state of the oscillator to 
downstream targets in order to generate the oscillatory output.151 There are two types of 
bacterial oscillators: Temporal oscillators which incorporate the periodic accumulation or 
activity of a protein to drive temporal cycles such as the cell and circadian cycles,315 and 
spatial oscillator which incorporate the periodic variation in the localization of a protein 
to define subcellular positions such as the site of cell division316-317 and the localization of 
DNA.318  However, the mechanisms of how these oscillators are designed and function 
are still unclear.  
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Figure 6.12 Images of P. aeruginosa PA14 strain inoculated on the M8 swarm agar 
(0.5 % agar) plates with and without 85 µM of DSDS. Pictures were taken 24 h after the 
inoculation of bacteria on the plates. 
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6.2.6. Synthetic agents can destruct the bacterial surface of PAO1 and PA14 
 
To observe the effects of our molecules on the bacterial surfaces by using TEM, 
we cultured PAO1 with 20 µM of SFβM, and PA14 with 85 µM of SRβM and 170 µM of 
rhamnolipids (a mixture of 3:1 di- and mono-rhamnolipids) in LB media to an optical 
density about 0.4 to 0.5. We choose these polar hydrocarbons and concentrations because 
these conditions inhibited the swarming motilities of PAO1 and PA14. The bacterial 
culture solutions were directly placed on the copper grids for TEM, rinsed and then 
stained with uranyl acetate. Figure 6.13 showed that intact bacteria of PAO1 and PA14 
with some appendages readily visible for PAO1. In presence of 20 µM SFβM for PAO1, 
a drastic effect was observed on the surfaces of the bacteria. Debris was released from the 
bacteria, with some debris still attached to the bacteria. Similar phenomena were 
observed for PA14. With 85 µM SRβM, some debris was seen; and with 170 µM 
rhamnolipids, a considerable amount of debris was seen at the two polar ends of the 
PA14 strain. We note that at these conditions, the bacteria were not dead, but their 
pathogenic activities were grossly altered.  
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Figure 6.13 Transmission electron microscopy of PAO1, PA14, and Mucoid PA strain 
with and without treatment with their active agents in 4-h culture (OD=0.5). The samples 
were stained with 0.5% (wt/vol) uranyl acetate. 
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Figure 6.14 Hypothesis of Ligand Binding Causing Pili Assembly and Engine in 
Membrane to Disassemble  
In addition, to support the observation that our molecules disrupted the bacterial 
surfaces using TEM, we also examined the membrane protein composition using an 
alkaline buffer extraction method and then visualized by the SDS-PAGE gel. The result 
showed alkaline buffer extracted a sample of PAO1 treated with 45 µM SFβM had a 
significant decrease in protein expression at ~15 kDa than no agent control sample which 
indicates the disrupted protein is most likely to be pili protein since the molecular weight 
of pili protein is ~15-16 kDa region (Figure 6.15). As for the cause of the increase in the 
protein expression at ~34 kDa and ~55 kDa range is not clear. However, the possible 
surface protein that has a molecular weight of 34~55 kDa can be Putative pili assembly 
chaperone, Type IV pili twitching motility protein PilT, Phosphate-binding protein PstS 
or Pili assembly chaperone (see Table 6.1). These results support the hypothesis that our 
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molecules target the pili assemblies of the bacteria, and because of the control of 
bioactivities, induced a wide range of bacterial signaling events.  
 
Figure 6.15 SDS-PAGE gel image of alkaline buffer extracted bacterial surface protein 
composition. Samples were prepared from PAO1 bacteria cultures grown with and 
without agents and purified by alkaline buffer extraction.  
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Table 6.1 List of 9 possible surface proteins at 30-50 kDa range in Pseudomonas 
aeruginosa species (source; http://www.uniprot.org/uniprot/) 
 
 
6.2.7. The synthetic agent can inhibit twitching motilities of P. aeruginosa in solution  
 
In order to have direct observation of the effect of our molecules on the motilities 
of bacteria at the level of an individual bacterium, we observe the motility of individual 
bacterium of P. aeruginosa that express fluorescent proteins PAO1-EGFP under a 
confocal microscope. We discovered that without the presence of our agents, in every 
second, there is about 7% of bacteria will either move in or out of the focal plane of the 
fluorescence due to swimming or twitching motilities. However, in the presence of SFβM 
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(10 µM, 6.1 µg/mL) and over the duration of 1 second, the entire bacteria population is 
not motile (Figure 6.16). This inhibition of bacterial solution-based twitching and 
swimming motility further supports that our agents bind to pili, and perhaps also flagella, 
and inhibit the dynamic of these appendages (extension and retraction for pili, and 
rotation for flagella).  
 
 
Figure 6.16 One-second time lapse of confocal fluorescence of PAO1-EGFP (OD= 0.3 to 
0.4) with and without 10 µM SFβM in the media. The images at the 3rd and 4th second 
were shown; the red circles indicate changes: bacteria that move bacteria into (appear) 
and out of (disappear) the focal plane due to the twitching motion. The numbers of 
“appear” and “disappear” bacteria are plotted for the bacterial sample without the agent 
(empty triangles) and sample with 10 µM SFβM (filled circle).   
 142 
 
6.2.8. Attempts at making a fluorescently tagged pilin ligand 
 
In order to obtain more direct evidence of ligand-receptor binding between our 
molecules and pili appendage on bacterial surfaces, we designed ligand molecules with 
covalently attached fluorescent tags, and explore their use of direct observation of 
fluorescently active surface appendages on bacteria, and of fluorescent polarization. 
  
In the past, such direct observations were obtained by modifying the amino acid 
of pilin monomers with cysteine amino acid, which will covalent attach to a fluorescent 
label. This approach enables a “live” observation of the dynamics and biology of the pili 
appendages. Another approach involves direct binding of a fluorescently active antibody 
to pilin of the pili appendage and makes a direct observation on the microscope.  
 
Because our indirect evidence suggests that our molecules bind to pili assembly 
on bacterial surfaces, we explore the following design of fluorescently labeled ligand 
molecules. Synthesis schemes for two fluorescent tagged DSDs, Pyrenyl-C11-βM (18) 
and UmDeβM (24) were shown in Scheme 6.1. However, the separation of Pyrenyl-C11-
βM encountered the major difficulty that most of the compound was stuck with the resin 
in the last deacylation step. According to the 1H NMR spectra of the Pyrenyl-C11-βM 
(18), most of the -OH peaks were disappeared from the final product. UmDeβM (24) has 
been successfully synthesized and the swarming assay was tested for this molecule. 
Unfortunately, UmDeβM did not show any modulating effect on the swarming motility 
of both PAO1 and rhlA strains of Pseudomonas aeruginosa (Figure 6.17). 
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Scheme 6.1. Synthesis schemes for fluorescent-tagged DSDs 
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Figure 6.17 Images of swarming motilities of PAO1 and rhlA on agar plates containing 
different concentrations of UmDeβM. The compound does not promote swarming of rhlA 
or promote tendril formation in PAO1. 
6.3. Conclusions 
 
Molecules capable of covalent ligation were designed and synthesized, and their 
multiple biological effects on P. aeruginosa bacteria were tested. The results show that 
one of our synthetic molecules SF(EG)4-epoxy is nontoxic and no biofilm Inhibition 
effect but capable of controlling bacterial swarming of PAO1. Pili protein was 
successfully purified by using P. aeruginosa bacteria strain that can overproduce pili 
proteins. To study the potential interaction between our synthetic molecules and pilin 
proteins, mixing experiment were done by using the pili protein and several other 
proteins (Lysozyme and BSA) with the synthetic molecule SF(EG)4-epoxy, which is 
capable of covalent ligation. The results indicate that SF(EG)4-epoxy can covalently 
attach to the receptor protein ONLY when the ligand-receptor take place. Swarming 
motility of P. aeruginosa was tested with protein solutions (Pili protein and BSA) spread 
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on agar gel. Pili protein inhibits swarming of PAO1 and also inhibits swarming of rhlA in 
the presence of 85 µM DβM (this condition was supposed to promote swarming of rhlA). 
While BSA does not inhibit swarming of PAO1, and rhlA in the presence of 85 µM 
DβM. The results further indicate that pili are the receptor (or one of the receptors) that 
will bind to rhamnolipids and our synthetic agents, and upon binding, causing the 
bacterial activities. We also imaged damaged pili on bacterial surfaces using TEM. These 
results indicate that pili appendage is the target of SFβM. 
 
6.4. Materials and Methods 
 
6.4.1. Stock solutions of generic surfactants and maltose derivatives 
A stock solution of all the agents was prepared in autoclaved water, sterilized by 
filtering through a 0.2 μm 16 syringe filter, and stored at -20 °C in sealed vials. An 
appropriate amount of sterile water was added to controls in all assays to eliminate the 
solvent effect.  
 
6.4.2. Swarming assay  
Swarm agar plates were made using M8 medium supplemented with 0.2% 
glucose, 0.5% casamino acid, 1 mM MgSO4 and solidified with 0.5 % Bacto agar. 
Bacterial culture with OD600 between 0.4 to 0.6 was inoculated as 3 μl aliquots. Swarm 
agar plates were incubated at 37 °C for 12 h and then incubated for an additional 12 h at 
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rt. For each set of the experiment all the swarm plates were poured from the same batch 
of agar and allowed to dry for 1 h before inoculation of bacteria.  
 
6.4.3. Crystal violet dye-based biofilm inhibition assay  
Inhibitory effect of all the maltose hydrocarbons on P. aeruginosa biofilm 
formation was determined by crystal violet dye-based biofilm inhibition assays. An 
overnight culture of wild-type P. aeruginosa (PAO1) was subcultured to an OD600 of 
0.01 into the 95/5 M9+/LB medium (The places where only LB medium has been used is 
indicated in the figure caption). 200 μL of the subculture was aliquoted into the wells of 
96 well polystyrene microtiter plate when it reached the OD600 of 0.1. Predetermined 
concentrations of the test compounds were then added to the respective wells containing 
subculture. Sample plates were wrapped in GLAD Press n’ Seal® followed by incubation 
under stationary conditions for 24 h at 37 °C. After incubation, the media was discarded, 
and the plates were washed with water and dried for 1 h at 37 °C. The sample plates were 
stained with 200 μL of 0.1% aqueous solution of crystal violet (CV) and followed by 
incubation at ambient temperature for 20 min. The CV stain was then discarded, and the 
plates were washed with water. The remaining biofilm adhered stain was re-solubilized 
with 200 μL of 30 % acetic acid. After the stain was dissolved (15 minutes), 100 μL of 
the solubilized CV was transferred from each well into the corresponding wells of a new 
polystyrene microtiter dish. Biofilm inhibition was quantified by measuring the OD600 
of each well in which a negative control lane wherein no biofilm was formed served as a 
background and was subtracted out. The percent inhibition was calculated by the 
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comparison of the OD600 for biofilm grown in the absence of compound (control) versus 
biofilm grown in the presence of compound under identical conditions.  
 
6.4.4. Solution-based bacteria twitching assay.   
An overnight culture of bacteria was subcultured to an OD600 of 0.01 into the LB 
medium containing predetermined concentrations of the test compounds. 10 µL of the 
subculture was transferred onto a glass slide when it reached the OD600 of 0.3-0.4. 
Twitching motilities were visualized using a Zeiss LSM 710 Confocal Laser Scanning 
Microscope (Carl Zeiss, Jena, Germany). A 488 nm laser line was used to visualize 
twitching motilities of PAO1-EGFP strain.  
 
6.4.5. Ligand-Pili receptor conjugation reactions.  
300 µL of SF(EG)4-epoxy (50 equiv., 1.6 mg) from a stock solution of 11.5 mM 
in deionized water (18.2 MΩ.cm) was added to a 1 mL solution containing 1 mg/mL 
lysozyme (14307 Da) or pili protein (15648 Da) or bovine serum albumin protein 
(~66000 Da) in PBS pH 8.2 (reaction buffer). The reaction mixture was shaken at 250 
rpm for 24 h at ambient temperature in a shaker-incubator. These samples were sent out 
for MALDI-MS at Rutgers University (http://cabm-ms.cabm.rutgers.edu/) to characterize 
the potential covalent modification of the proteins. 
 
6.4.6. Transmission electron microscopy. 
 
 148 
 
A small number of bacteria from the edge or the center of the colony on the 
swarming plate was picked using a sterile toothpick and dispersed in PBS buffer by 
gently touching the toothpick to the liquid for 5 s. A droplet of the bacterial suspension 
was placed onto a copper TEM grid. After waiting for 15 min, the remaining solution was 
wicked away using a piece of filter paper. The samples were then rinsed with 2 ml of 2 
mM HEPES buffer (pH 6.8) followed by a rinse with 1 ml of MilliQ water. The samples 
were then stained by placing a drop of 0.5% (wt/vol) uranyl acetate onto the samples and 
removing the excess by wicking with filter paper after 3 to 5 min. TEM pictures were 
imaged using a 120 kV field FEI T12 Spirit TEM Equipped with a LaB6 filament, single 
and double tilt holder, an SIS Megaview III CCD camera, and a STEM dark field and 
bright field detector, along with analysis and imaging software. 
 
 
6.4.7. Alkaline buffer extraction.    
 
Set up overnight cultures for P. aeruginosa from frozen stocks. Conditions: 10 ml 
LB broth in 50 ml Falcon tube at 37 °C shaking at 200 rpm. Next day, set up fresh cultures 
from the overnight cultures in new LB broth using a 1:100 ratio dilution, and grow at 37 
°C shaking at 200 rpm until the exponential growth phase (0.4 - 0.6 OD600). Centrifuge the 
culture at 3,000 x g for 5 min at 4 °C. Discard the supernatant and gently resuspend the 
pellet in 10 ml of PBS. Centrifuge at 3,000 x g for 10 min at 4 °C, discard supernatant and 
resuspend pellet in 3 ml 20 mM Tris pH 7.4. Centrifuge at 3,000 x g for 10 min at 4 °C , 
discard the supernatant and resuspend the pellet in 0.1 M Na2CO3. Keep on ice for 30 min. 
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Use 1 mL syringe pass cells suspension through a >22-gauge needle 10 times (or other 
gentle cells lyse methods). Centrifuge 3,000 x g for 20 min at 4 °C to remove unlysed 
cells. Resuspend the pellet in 0.1 M Na2CO3, re-extract as above and pool the 
supernatants. Combine the supernatants and neutralize by adding HCl drop by drop. The 
supernatant is transferred to a fresh tube and centrifuged at 30,000 x g for 40 minutes at 4 
°C. Take off the supernatant and the left pellets are ready for running SDS-PAGE.  
 
6.4.8. Synthetic procedures  
 
 
Scheme 6.2. Synthesis scheme for ChC3βM 
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β-cholestanone (2) 
Lit. ref. for characterization data: Org. Lett. 2013, 15, 992-995.  
To a suspension of pyridinium chlorochromate (2.21 g, 10.29 mmol) and silica gel 
(2.21 g) in 10 mL dichloromethane, β-cholestanol (1) (2.0 g, 5.14 mmol) dissolved in 10 
mL dichloromethane was added. The resulting black/orange solution was stirred at room 
temperature for 4 h. The reaction mixture was then filtered through a bed of silica gel. The 
residue was washed with dichloromethane. The filtrate was concentrated to afford β-
cholestanone (1.91 g, 96%) as a white solid. White powder; TLC: Rf = 0.36 (10% ethyl 
acetate/90% hexanes); 1H NMR (CDCl3, 400 MHz): δ 2.37-2.30 (m, 3H), 2.26-0.85 (m, 
40H), 0.68 (s, 3H). 
 
 
(3) 
A solution of 2 (1.5 g, 3.88 mmol) and 1, 3-butanediol (1.0 g, 11.1 mmol) was 
refluxed overnight under toluene (25 ml) in the presence of pyridinium p-toluenesulfonate 
(50 mg). Molecular sieve (type 3A) was added to remove water formed during the reaction. 
Concentration and silica gel chromatography (elution with 3% ethyl acetate in hexane) 
afforded 3 (1.5 g, 3.31 mmol, 85%) as a white solid. TLC: Rf = 0.60 (5% ethyl acetate/95% 
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hexanes); 1H NMR (CDCl3, 400 MHz): δ 3.82-3.74(m, 2H), 3.61(m, 1H), 3.50(m, 1H), 
2.26-0.85 (m, 47H), 0.68 (s, 3H). 
 
 
 
(4a) 
Add 3 (1.2 g, 2.6 mmol) in 8 mL anhydrous ether to a previously prepared 
solution of LiAIH(0.30 g, 7.5 mmol) and A1C13 (0.35 g, 2.5 mmol) in 8 mL anhydrous 
ether. The reduction was allowed to proceed at room temperature for 12 h. Then 15% 
aqueous KOH was added dropwise to decompose the complex and form a colorless 
precipitate which was readily removed by filtration. Concentration and silica gel 
chromatography (elution with 3% ethyl acetate in hexane) afforded 4a (0.62 g, 1.3 mmol, 
50%). TLC: Rf = 0.70 (15% ethyl acetate/85% hexanes); 1H NMR (CDCl3, 400 MHz): δ 
3.50-3.70(m, 4H), 3.38-3.30(m, 1H), 2.26-0.55 (m, 50H). 
 
 
(4b) 
Add 3 (1.2 g, 2.6 mmol) in 8 mL anhydrous ether to a previously prepared 
solution of LiAIH(0.30 g, 7.5 mmol) and A1C13 (0.35 g, 2.5 mmol) in 8 mL anhydrous 
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ether. The reduction was allowed to proceed at room temperature for 12 h. Then 15% 
aqueous KOH was added dropwise to decompose the complex and form a colorless 
precipitate which was readily removed by filtration. Concentration and silica gel 
chromatography (elution with 3% ethyl acetate in hexane) afforded 4b (0.30 g, 1.3 mmol, 
24%). TLC: Rf = 0.65 (15% ethyl acetate/85% hexanes); 1H NMR (CDCl3, 400 MHz): δ 
3.64-3.58(m, 3H), 3.45-3.37(m, 1H), 3.24-3.15(m, 1H), 2.26-0.50 (m, 50H). 
 
 
(6a) 
Maltose (0.2 g, 0.5mmol), AcBr (~0.6mL, 8 mmol), and AcOH (5mL) were 
added to an oven dried round bottom flask and stirred at room temperature (25 ⁰C) for ~ 
1 h. The reaction mixture was concentrated in vacuo at 35 ⁰C and then co-evaporated 
three times with PhMe (2×10 mL, anhydrous). After removal of solvent, the flask was 
further heated in vacuo at 50 ⁰C for 15min to give a foamy solid, aceto-bromo sugar. The 
crude aceto-bromo sugars were immediately used in next step without any further 
purification. 
Crude aceto-bromo sugars were the dissolved in MeCN (10mL) and 4a (1.0mmol, 2 
equivalents) were added along with acid 2-equivalents of a Lewis catalyst FeCl3. The 
reaction mixture was stirred vigorously for about ~45-60 mins at rt. After stirring at rt, aq 
KBr (10%, 25mL) and then PhMe (60mL) were added under stirring. The organic phase 
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was washed twice with aq KBr (10%, 2×25mL), once with aq NaHCO3 (5%, 25mL) and 
twice with H2O (2×25mL). The crude product was then purified by column 
chromatography using gradient elution (100 % hexane to 35 % ethyl acetate in hexane). 
Concentration and silica gel chromatography afforded 6a (0. 22g, 0.2 mmol, 20%) TLC: 
Rf = 0.45 (35% ethyl acetate/65% hexanes); 1H NMR (CDCl3, 400 MHz): δ 5.43-5.33 (m, 
2H), 5.29-5.26 (m, 1H), 5.09-5.02(m, 1H), 4.89-4.79 (m, 2H), 4.52 – 4.45 (m, 2H), 4.29 – 
4.21 (m, 2H), 4.06-3.93 (m, 3H), 3.88 – 3.68 (m, 2H), 3.52 – 3.35 (m, 2H), 3.30-3.15(m, 
2H) 2.15 – 2.01 (s, 7 × 3 H), 2.26-0.50 (m, 50H). 
 
 
 
(6b) 
Maltose (0.2 g, 0.5mmol), AcBr (~0.6mL, 8 mmol), and AcOH (5mL) were 
added to an oven dried round bottom flask and stirred at room temperature (25 ⁰C) for ~ 
1 h. The reaction mixture was concentrated in vacuo at 35 ⁰C and then co-evaporated 
three times with PhMe (2×10 mL, anhydrous). After removal of solvent, the flask was 
further heated in vacuo at 50 ⁰C for 15min to give a foamy solid, aceto-bromo sugar. The 
crude aceto-bromo sugars were immediately used in next step without any further 
purification. 
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Crude aceto-bromo sugars were the dissolved in MeCN (10mL) and 4a (1.0mmol, 2 
equivalents) were added along with acid 2-equivalents of a Lewis catalyst FeCl3. The 
reaction mixture was stirred vigorously for about ~45-60 mins at rt. After stirring at rt, aq 
KBr (10%, 25mL) and then PhMe (60mL) were added under stirring. The organic phase 
was washed twice with aq KBr (10%, 2×25mL), once with aq NaHCO3 (5%, 25mL) and 
twice with H2O (2×25mL). The crude product was then purified by column 
chromatography using gradient elution (100 % hexane to 35 % ethyl acetate in hexane).  
Concentration and silica gel chromatography afforded 6b (0. 37g, 0.35 mmol, 32%) TLC: 
Rf = 0.40 (35% ethyl acetate/65% hexanes); 1H NMR (CDCl3, 400 MHz): δ 5.43-5.33 
(m, 2H), 5.29-5.26 (m, 1H), 5.09-5.02(m, 1H), 4.89-4.79 (m, 2H), 4.52 – 4.45 (m, 2H), 
4.29 – 4.21 (m, 2H), 4.06-3.93 (m, 3H), 3.88 – 3.68 (m, 2H), 3.55 – 3.32 (m, 3H), 3.32-
3.17(m, 1H) 2.15 – 2.01 (s, 7 × 3 H), 2.26-0.50 (m, 50H). 
 
 
(7a) 
Zemplén deacetylation. For all acetylated sugar-derivatized hydrocarbon 
molecules, the deprotection of alcoholic groups was achieved by Zemplén deacetylation 
using MeONa/MeOH (10 mM solution) conditions followed by neutralization (pH ~6.5) 
over H+ amberlite resins. The resins were filtered off and products dried under high 
vacuum overnight. White solid, Yield: 7a (0.07 g, 88 %), 1H-NMR (CD3OD, 400 MHz): 
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δ 5.17 (d, J = 3.6 Hz, 1H), 4.28 (d, J = 7.8 Hz, 1H), 3.92-3.78 (m, 4 H), 3.72 – 3.15 (m, 
15H, overlapping with CD3OD), 2.26-0.50 (m, 50H). 
 
  
Scheme 6.3. Synthesis scheme for TEGβM 
 
 
 
(8) 
Maltose (1.0 g, 2.8mmol), AcBr (~3.6mL, 44.4mmol), and AcOH (19mL) were 
added to an oven dried round bottom flask and stirred at room temperature (25 ⁰C) for ~ 
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1 h. The reaction mixture was concentrated in vacuo at 35 ⁰C and then co-evaporated 
three times with PhMe (2×10 mL, anhydrous). After removal of solvent, the flask was 
further heated in vacuo at 50 ⁰C for 15min to give a foamy solid, aceto-bromo sugar. The 
crude aceto-bromo sugars were immediately used in next step without any further 
purification. 
Crude aceto-bromo sugars were then dissolved in MeCN (10mL) and TEG 
(5.6mmol, 2 equivalents) were added along with acid 2-equivalents of a Lewis catalyst 
FeCl3. The reaction mixture was stirred vigorously for about ~45-60 mins at rt. After 
stirring at rt, aq KBr (10%, 25mL) and then PhMe (60mL) were added under stirring. The 
organic phase was washed twice with aq KBr (10%, 2×25mL), once with aq NaHCO3 
(5%, 25mL) and twice with H2O (2×25mL). The crude product was then purified by 
column chromatography using gradient elution (100 % hexane to 50 % ethyl acetate in 
hexane). Concentration and silica gel chromatography afforded 8 (0.6 g, 0.8 mmol, 29%) 
TLC: Rf = 0.55 (50% ethyl acetate/50% hexanes); 1H NMR (CDCl3, 400 MHz): δ 5.62-
5.55(m, 1H), 5.38-5.30(m, 2H), 5.08-4.95(m, 1H), 4.86-4.80(m, 1H), 4.70-4.65(m, 1H), 
4.52-4.45(m, 1H), 4.30-4.17(m, 3H), 4.12-3.98(m, 3H), 3.93-3.88(m, 1H), 2.15 – 2.01 (s, 
7 × 3 H). 
 
 
(9) 
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Zemplén deacetylation. For all acetylated sugar-derivatized hydrocarbon 
molecules, the deprotection of alcoholic groups was achieved by Zemplén deacetylation 
using MeONa/MeOH (10 mM solution) conditions followed by neutralization (pH ~6.5) 
over H+ amberlite resins. The resins were filtered off and products dried under high 
vacuum overnight. White solid. Yield: 9 (0.35 g, 85 %), 1H NMR (CDCl3, 400 MHz): δ 
5.20-5.16 (m, 1H), 4.26-4.21 (m, 1H), 3.97-3.88 (m, 1H), 3.82-3.40 (m, 17H), 3.38-
3.27(m, 2H),3.22-3.12 (m, 4H). 
Scheme 6.4. Synthesis scheme for TGMEβM 
 
 158 
 
 
(10) 
Maltose (1.0 g, 2.8mmol), AcBr (~3.6mL, 44.4mmol), and AcOH (19mL) were 
added to an oven dried round bottom flask and stirred at room temperature (25 ⁰C) for ~ 
1 h. The reaction mixture was concentrated in vacuo at 35 ⁰C and then co-evaporated 
three times with PhMe (2×10 mL, anhydrous). After removal of solvent, the flask was 
further heated in vacuo at 50 ⁰C for 15min to give a foamy solid, aceto-bromo sugar. The 
crude aceto-bromo sugars were immediately used in next step without any further 
purification. 
Crude aceto-bromo sugars were the dissolved in MeCN (10mL) and TGME 
(5.6mmol, 2 equivalents) were added along with acid 2-equivalents of a Lewis catalyst 
FeCl3. The reaction mixture was stirred vigorously for about ~45-60 mins at rt. After 
stirring at rt, aq KBr (10%, 25mL) and then PhMe (60mL) were added under stirring. The 
organic phase was washed twice with aq KBr (10%, 2×25mL), once with aq NaHCO3 
(5%, 25mL) and twice with H2O (2×25mL). The crude product was then purified by 
column chromatography using gradient elution (100 % hexane to 50 % ethyl acetate in 
hexane). Concentration and silica gel chromatography afforded 10 (0.6 g, 0.8 mmol, 
29%) TLC: Rf = 0.55 (50% ethyl acetate/50% hexanes); 1H NMR (CDCl3, 400 MHz): δ 
5.62-5.40(m, 2H), 5.38-5.22(m, 1H), 5.08-4.95(m, 1H), 4.90-4.78(m, 2H), 4.65-4.60(m, 
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1H), 4.52-4.45(m, 1H), 4.30-4.17(m, 2H), 3.93-3.85(m, 5H), 3.76-3.52(m, 11H), 3.38 (s, 
3H), 2.15 – 2.01 (s, 7 × 3 H). 
 
 
(11) 
Zemplén deacetylation. For all acetylated sugar-derivatized hydrocarbon 
molecules, the deprotection of alcoholic groups was achieved by Zemplén deacetylation 
using MeONa/MeOH (10 mM solution) conditions followed by neutralization (pH ~6.5) 
over H+ amberlite resins. The resins were filtered off and products dried under high 
vacuum overnight. 1H-NMR (CD3OD, 400 MHz): δ 5.20-5.16 (m, 1H), 4.26-4.21 (m, 
1H), 3.97-3.88 (m, 1H), 3.82-3.40 (m, 20H), 3.38 (s, 3H),3.36-3.24 (m, 3H). 
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Scheme 6.5. Synthesis scheme for SRβM   
 
 
(14) 
Add 1 equivalent of retinol acetate and 10 equivalents of 10% Pd/C in EtOAc. 
Hydrogenation is proceeded under 125 psi hydrogen.  The reaction was filtered over 
celite and washed with EtOAc to remove any excess product in the celite. Slowly add 1 
equiv. LAH to a solution of saturated retinol acetate in THF(0.2M) at 0ºC.  Allow to 
warm to room temperature and stir for 16h.  The reaction was filtered over celite and the 
filtrate was concentrated to dryness without further purifications.  
To an oven dried round bottom flask, disaccharide (maltose, cellobiose) (1.0 g, 
2.8mmol), AcBr (~3.6mL, 44.4mmol), and AcOH (19mL) were added and stirred at 
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room temperature (25 ⁰C) for ~ 1 h. The reaction mixture was concentrated in vacuo at 
35 ⁰C and then co-evaporated three times with PhMe (2×10 mL, anhydrous). After 
removal of solvent, the flask was further heated in vacuo at 50 ⁰C for 15min to give a 
foamy solid, aceto-bromo sugar. The crude aceto-bromo sugars were immediately used in 
next step without any further purification. The crude aceto-bromo sugars were then 
dissolved in MeCN (10mL) and saturated retinol (5.6mmol, 2 equivalents) were added 
along with two equivalents of FeCl3.The reaction mixture was stirred vigorously for 
about ~45-60 mins at rt. After stirring at rt, aq KBr (10%, 25mL) and then PhMe (60mL) 
were added under stirring. The organic phase was washed twice with aq KBr (10%, 
2×25mL), once with aq NaHCO3 (5%, 25mL) and twice with H2O (2×25mL). The crude 
product was then purified by column chromatography using gradient elution (100 % 
hexane to 35 % ethyl acetate in hexane).  Concentration and silica gel chromatography 
afforded 14 (0. 37g, 0.35 mmol, 32%) TLC: Rf = 0.40 (35% ethyl acetate/65% hexanes); 
1H NMR (CDCl3, 400 MHz): δ 5.43-5.33 (m, 2H), 5.29-5.26 (m, 1H), 5.09-5.02(m, 1H), 
4.89-4.79 (m, 2H), 4.52–4.45 (m, 2H), 4.29–4.21 (m, 2H), 4.06-3.93 (m, 3H), 3.88–3.68 
(m, 2H), 3.55 – 3.32 (m, 3H), 3.32-3.17(m, 1H) 2.15-2.01 (s, 7 × 3 H), 1.52-0.83 (m, 37H 
aliphatic chain). 
 
 
 
(15) 
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The deprotection of acetyl groups was achieved by Zemplén deacetylation using 
MeONa/MeOH (10 mM solution) conditions followed by neutralization (pH ~6.5) over 
H+ amberlite resins. The resins were filtered off and products dried under high vacuum 
overnight. 1H-NMR (CD3OD, 400 MHz): δ 5.17 (br, s, 1H), 4.27 (d, J = 9 Hz, 1H), 3.95-
3.92 (m, 4H), 3.88-3.43 (m, 6H, overlap with CD3OD peak), 3.27-3.20 (m, 4H), 1.60-
0.88 (m, 37H aliphatic chain). 
 
 
 
(16) 
1-(1-pyrenyl)-11-bromo-1-undecanone 
In a 5 mL round bottom flask, 1.8 mL (24.8 mmol) of thionyl chloride was added 
to 1.0 g (3.8 mmol) of 11-bromoundecanoic acid. The mixture was heated at 40°C for 4 h 
and then stirred at room temperature for 12 h. After removal of the excess of thionyl 
chloride by rotavap, the residual colorless oil was dissolved in 6 mL of dry CH2Cl2, 
transferred in a two neck round bottom flask, and cooled to 0°C in an ice bath. Upon 
addition of 0.72 g (3.6 mmol) of pyrene and 0.57 g (4.3 mmol) of AlCl3, the reaction was 
stirred for 5 h at 0°C. The reaction mixture was then poured on an ice/water/Et2O 
mixture. The organic layer was washed three times with water and dried over Mg2SO4. 
After removal of solvent, purification of the crude product on silica gel, using 
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hexane/Et2O (9:1) as eluent, yielded the intermediate product I as a yellow solid (98%). 
1H NMR (CDCl3, 400 MHz): 8.93 (d, 1H, Ar), 7.92-8.31 (m, 8H, Ar), 3.44 (t, 2H, CH2 
ω), 3.22 (t, 2H, CH2 α), 1.94 (m, 2H, CH2 ω-1), 1.22-1.53 (m, 14H, aliphatic chain). 
 
 
(17) 
 
11-(1-pyrenyl)-1-bromoundecene was prepared according to a reported procedure. 
Briefly, in a two-neck, round bottom flask fitted with a reflux condenser, 0.45 g (3.4 
mmol) of AlCl3 dissolved in 5 mL of dry Et2O were added dropwise to a 1 M solution of 
LiAlH4 in dry Et2O. Then, 0.5 g (1.1 mmol) of 16 dissolved in 10 mL of dry CH2Cl2 were 
added dropwise to the mixture cooled to 0 °C in an ice bath, and the reaction mixture was 
stirred at room temperature and monitored by TLC (hexane/Et2O 9:1) until disappearance 
of 16 (~3 h). The reaction was quenched by the addition of 10 mL of Et2O and 10 mL of 
water; the organic layer was washed several times with HCl 1 M and dried over Mg2SO4. 
Removal of the solvent yielded a yellow solid (90%). 1H NMR (CDCl3, 400 MHz): 7.74-
8.22 (m, 9H, Ar), 3.3 (m, 4H), 1.1-1.9 (m, 18H, aliphatic chain). 
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(18) 
A mixture of 17 (200mg, 0.56mmol) and NaHCO3 (320mg, 3.8mmol) in DMSO 
(3.8mL) was heated to reflux for 1 h. Then saturated NaHCO3 solution and CH2Cl2 were 
added at room temperature. The organic layer was extracted with saturated NaCl solution, 
dried (MgSO4), and evaporated and the residue was purified by flash chromatography 
(hexane/ EtOAc 3:1) to give 97 mg (59%) as a colorless solid. 1H NMR (CDCl3, 400 
MHz): δ 9.77(t, 1H), 7.72-8.24 (m, 9H, Ar), 3.32(t, 2H), 2.41(t, 2H), 1.14-1.92 (m, 18H). 
 
 
 
(19)  
(Need repeat) 
Maltose (1.0 g, 2.8mmol), AcBr (~3.6mL, 44.4mmol), and AcOH (19mL) were 
added to an oven dried round bottom flask and stirred at room temperature (25 ⁰C) for ~ 
1 h. The reaction mixture was concentrated in vacuo at 35 ⁰C and then co-evaporated 
three times with PhMe (2×10 mL, anhydrous). After removal of solvent, the flask was 
further heated in vacuo at 50 ⁰C for 15min to give a foamy solid, aceto-bromo sugar. The 
 165 
 
crude aceto-bromo sugars were immediately used in next step without any further 
purification. 
Crude aceto-bromo sugars were then dissolved in MeCN (10mL) and 18 
(5.6mmol, 2 equivalents) were added along with acid 2-equivalents of a Lewis catalyst 
FeCl3. The reaction mixture was stirred vigorously for about ~45-60 mins at rt. After 
stirring at rt, aq KBr (10%, 25mL) and then PhMe (60mL) were added under stirring. The 
organic phase was washed twice with aq KBr (10%, 2×25mL), once with aq NaHCO3 
(5%, 25mL) and twice with H2O (2×25mL). The crude product was then purified by 
column chromatography using gradient elution (100 % hexane to 50 % ethyl acetate in 
hexane). Concentration and silica gel chromatography afforded the acetylated product 
(0.6 g, 0.8 mmol, 29%). The deprotection of acetyl groups was achieved by Zemplén 
deacetylation using MeONa/MeOH (10 mM solution) conditions followed by 
neutralization (pH ~6.5) over H+ amberlite resins. The resins were filtered off and 
products dried under high vacuum overnight. 1H NMR (400 MHz, MeOD) showed the 
product is not pure, need to synthesize this again. 
 
 
1,10-Decanediol di-p-tosylate, TsOC10H20OTs (20) 
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 In an overnight oven-dried round bottom flask, 1, 10-decanediol (1 g, 5.7 mmol) 
and 4-toluenesulfonyl chloride (2.3 g, 12 mmol) were dissolved in dry dichloromethane 
(60 ml) at 0 °C. Upon the addition of pyridine (0.94 g, 12 mmol) the reaction mixture 
was allowed to stir vigorously under argon environment and warmed to room temperature 
overnight. The reaction mixture was concentrated in vacuo. The reaction crude was 
diluted with 1:1 H2O:CH2Cl2 (120 ml). The organic layer was washed with brine (3*30 
ml) and dried over Na2SO4. Upon removal of solvents, 1,10-Decanediol di-p-tosylate was 
afforded as a white solid (2.29 g, 4.8 mmol, 98%). TLC: Rf=0.48 (hexanes:ethyl acetate, 
7:3). 1H NMR (CDCl3, 400 MHz): δ 7.79 (4H, d, J=8 Hz, -C2H4C2H4CS-), 7.34 (4H, d, 
J=8 Hz, CH3CC2H4C2H4-), 4.00 (4H, t, J=6.8 Hz, TsOCH2CH2-), 2.45 (6H, s, -PhCH3), 
1.62 (4H, p, J=6.8 Hz, TsOCH2CH2-), 1.2 (6H, s, b, Aliphatic), 1.18 (6H, s, b, Aliphatic).  
 
 
UmOC10H20OTs (21) 
 
 In an overnight oven-dried round bottom flask, umbelliferone (0.162 g, 1 mmol) 
was dissolved in dry MeCN (10 ml), and K2CO3 (0.140 g, 1 mmol) was added. The 
reaction mixture was stirred at room temperature for 15 minutes, then treated with 1, 10-
decandiol ditosylate (1.01 g, 2.1 mmol). The reaction mixture was heated with an oil bath 
to 65 ˚C and allowed to stir vigorously at for 12 h under Ar environment. After cooling, 
the reaction mixture was concentrated, diluted with 1:1 CH2Cl2: H2O (20 ml). The 
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organic layer was washed with brine, dried over MgSO4, and concentrated in vacuo. The 
reaction crude was diluted with CH2Cl2, mixed with SiO2 (80%). Upon removal of the 
solvent, the crude mixture was purified with flash chromatography (hexane: ethyl acetate, 
3:1) to give Umbelliferone Decanol Tosylate Ether as a colorless oil (0.223g, 0.47 mmol, 
47%). TLC: Rf=0.34 (hexanes:ethyl acetate, 7:3). 
1H NMR (CDCl3, 400 MHz): δ 7.80 
(2H, d, J=8.4 Hz, -C2H4C2H4CS-), 7.64 (1H, d, J=9.6 Hz, -CH=CHC-), 7.37 (2H, d, 
J=8.4 Hz, CH3CC2H4C2H4-), 7.35 (1H, d, J=6.8 Hz, -CHCHC(OH)-), 6.84 (1H, dd, 
J=8.8, 2.4 Hz, -CCHCH-), 6.81 (1H, d, J=2 Hz, -CCHC(OH)-), 6.25 (1H, d, J=9.6 Hz, -
OC(=O)CH=CHC-), 4.03 (2H, t, J=6.8 Hz, UmOCH2CH2-), 4.0 (2H, t, J=6.8 Hz, 
TsOCH2CH2-), 2.46 (3H, s, -PhCH3), 1.81 (2H, p, J=6.8 Hz, Aliphatic), 1.65 (2H, p, 
J=6.8 Hz, Aliphatic), 1.69 (2H, d, J=7.6 Hz), 1.45 (2H, p, J=6.8 Hz, Aliphatic), 1.2-1.4 
(8H, m, Aliphatic).  
 
 
UmDe Alcohol, UmOC10H20OH (22) 
 
 In a clean and dry round bottom flask, UmDe Tosylate (0.443 g, 0.937 mmol) was 
dissolved in a stirring mixture of 0.5 M aq. NaOH (2 ml, 2 mmol) and MeCN (8 ml). The 
reaction mixture was heated with an oil bath to 78 ˚C and allowed to stir vigorously at for 
12 h. After cooling, the reaction mixture was quenched with 0.5 M HCl (2 ml, 2 mmol), 
concentrated, then diluted with 1:1 CH2Cl2: H2O (20 ml). The organic layer was washed 
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with brine, water, and dried over MgSO4, and concentrated in vacuo. Upon removal of 
the solvent, the crude mixture was purified with flash chromatography (hexane: ethyl 
acetate, 7:3) to give UmDe Alcohol as a white solid (26 mg, 0.082 mmol, 8.6%). TLC: 
Rf=0.24 (hexanes:ethyl acetate, 7:3). 
1H NMR (CDCl3, 400 MHz): δ 7.64 (1H, d, J=9.6 
Hz, -CH=CHC-), 7.36 (1H, d, J=6.8 Hz, -CHCHC(OH)-), 6.84 (1H, dd, J=8.8, 2.4 Hz, -
CCHCH-), 6.81 (1H, d, J=2 Hz, -CCHC(OH)-), 6.25 (1H, d, J=9.6 Hz, -
OC(=O)CH=CHC-), 4.02 (2H, t, J=6.4 Hz, UmOCH2CH2-), 3.66 (2H, t, J=6.4 Hz, 
HOCH2CH2-), 1.84 (2H, t, J=6.8 Hz, Aliphatic), 1.6-1.4 (10H, m, Aliphatic), 1.36 (8H, s, 
Aliphatic).  
 
 
Per-acetyl UmDeβM (23) 
To an oven dried round bottom flask, maltose (0.072 g, 0.2 mmol) was dissolved 
in AcOH (2 ml), then treated with AcBr (~0.30 mL, 4.0 mmol). The reaction mixture was 
allowed to stir at room temperature (25 ⁰C) for ~ 1 h. The reaction mixture was 
concentrated in vacuo at 35 ⁰C. After removal of solvent, the reaction crude was co-
evaporated with anhydrous toluene (2×3 mL) at 40 ⁰C to further remove residual acetic 
acid to give aceto-bromo sugars as a foamy solid. The crude aceto-bromo maltose was 
immediately used in next step without any further purification. The crude aceto-bromo 
maltose (~0.2 mmol) was dissolved in MeCN (10mL) along with UmOC10H20OH (0.096 
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g, 0.3 mmol). To this reaction mixture was added two FeCl3 (0.033 g, 0.4 mmol). The 
reaction mixture was stirred vigorously for about 60 mins at rt. Then 10% aq. KBr (3 ml) 
and toluene (5 ml) were added under stirring. The organic phase was subsequently 
washed with 10% aq. KBr (2×3 ml), 5% aq NaHCO3 (5%, 3 ml), and H2O (2×3 ml). 
Upon removal of solvent, the crude mixture was purified with flash chromatography 
(hexane: ethyl acetate, 1:1) to give Per-acetyl UmDeβM as a white solid (19 mg, 0.020 
mmol, 10%). TLC: Rf=0.29 (hexanes:ethyl acetate, 1:1). 1H NMR (CDCl3, 400 MHz): δ 
7.64 (1H, d, J=9.6 Hz, -CH=CHC-), 7.37 (1H, d, J=8.4 Hz, -CHCHC(OH)-), 6.84 (1H, 
dd, J=8.8, 2.4 Hz, -CCHCH-), 6.81 (1H, d, J=2 Hz, -CCHC(OH)-), 6.25 (1H, d, J=9.2 
Hz, -OC(=O)CH=CHC-), 5.43-5.34 (2H, m, maltose), 5.26 (1H, t, J = 9.2 Hz, anomeric), 
5.07 (1H, t, J = 9.6 Hz, anomeric), 4.89-4.80 (2H, m, maltose), 4.53-4.46 (2H, m, 
maltose), 4.28-4.22 (2H, m, maltose), 4.07-3.96 (2H, m, UmOCH2CH2-), 4.07-3.96 (2H, 
m, MOCH2CH2-), 4.07-3.96 (1H, m, -CHCH2OAc), 3.85 (1H, m, -CHCH2OAc), 3.67 
(1H, m, -CHCH2OAc), 3.47 (1H, m, -CHCH2OAc), 2.15-2.01 (7 x 3H, s, CH3C(=O)O-
),1.81 (2H, t, J=7.6 Hz, Aliphatic), 1.47 (2, t, J=7.6 Hz, Aliphatic), 1.45-1.25 (16H, m, 
Aliphatic). 
 
 
UmDeβM (24) 
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 To an oven dried round bottom flask, per-acetyl UmDeβM (30 mg, 32.02 mmol) 
was dissolved in 10 mM CH3ONa/CH3OH (10 ml). The reaction was allowed to stirred 
at room temperature under argon environment for 12 hours; then followed by 
neutralization (pH ~6.5) over H+ amberlite resins. After the resins were filtered off, the 
filtrate was concentrated in vacuo at 35 ⁰C to afford UmDeβM as a light-yellow solid (14 
mg, 21.78 mmol, 66%). TLC: Rf=0.18 (methanol). 1H NMR (CD3OD, 400 MHz): δ 7.88 
(1H, d, J=9.2 Hz, -CH=CHC-), 7.53 (1H, d, J=8.4 Hz, -CHCHC(OH)-), 6.92 (1H, dd, 
J=8.8, 2.4 Hz, -CCHCH-), 6.89 (1H, d, J=2 Hz, -CCHC(OH)-), 6.24 (1H, d, J=9.2 Hz, -
OC(=O)CH=CHC-), 4.26 (1H, d, J = 9.2 Hz, anomeric), 3.90-3.83 (5H, m, maltose), 4.07 
(2H, t, J=6.4 Hz, UmOCH2CH2-), 3.81 (1H, t, J = 6.4 Hz, anomeric), 3.80-3.65 (5H, m, 
maltose), 3.61 (2H, J=9.6 Hz, MOCH2CH2-), 3.6-3.5 (2H, m, -CHCH2OH), 3.3-3.2 (2H, 
m, -CHCH2OH), 1.81 (2H, t, J=7.2 Hz, Aliphatic), 1.62 (2H, t, J=7.6 Hz, Aliphatic), 1.50 
(2H, m, Aliphatic), 1.35 (10H, bs, Aliphatic). 
 
 
Scheme 6.6. Synthesis scheme for SF(EG)n-epoxy (n=3,4,5) 
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General procedure for the synthesis of SF(EG)nOH (n=3, 4, 5) 
Saturated farnesol (1 equiv.) and triphenylphosphine (1.1 equiv.) were dissolved in DMF 
under nitrogen atmosphere. Bromine was added drop by drop until the solution turned 
orange in color and flask temperature was maintained below 55 ºC. Reaction was allowed 
to stir at rt for additional 12 h. Reaction mixture was concentrated in vacuo and the 
resulting product was purified over column chromatography (15% EtOAc/hexanes) to 
afford the desired product SFBr. Then (EG)nOH (n=3, 4, 5) (2 equiv.) was dissolved in 
dry DMF and cooled to 0 ºC for 5 min. To the reaction mixture was added NaH (60% 
dispersion in mineral oil) (1 equiv.) at 0 °C and the reaction was further stirred for one 
hour. SFBr (1 equiv.) was added and the mixture was stirred at rt overnight. Reaction 
mixture was concentrated in vacuo and then dissolved in Et2O (15 mL). Organic layer 
was washed with water (10 mL x 3), brine and dried over Na2SO4. Organic phase was 
filtered and concentrated in vacuo. The reaction mixture was purified by column 
chromatography (40 % EtOAc/ Hexane) to afford SF(EG)nOH (n=3, 4, 5). 
 
 
SF(EG)3-epoxy (25) 
SF(EG)3OH (0.11 g, 0.30 mmol) was dissolved in 1 mL dry DMF and cooled to 0 ºC for 
5 min. To the reaction mixture was added NaH (60% dispersion in mineral oil) (0.04 g, 
0.33 mmol) at 0 °C and the reaction was further stirred for one hour. Epibromohydrin 
(0.05 g, 0.33 mmol) was added and the mixture was stirred at rt overnight. Reaction 
mixture was concentrated in vacuo and then dissolved in Et2O (5 mL). Organic layer was 
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washed with water (10 mL x 3), brine and dried over Na2SO4. Organic phase was filtered 
and concentrated in vacuo. The reaction mixture was purified by column chromatography 
(25 % EtOAc/ Hexane) to afford 25 (0.06 g, 47%). 1H NMR (400 MHz, CDCl3) δ 3.73 
(dd, 1H), 3.70-3.63 (m, 9H), 3.60-3.53(m, 1H), 3.51-3.38(m, 3H), 3.21-3.12 (m, 1H), 
2.84-2.77(m, 1H), 2.65-2.60 (m, 1H), 1.64-1.08 (m, 19H), 0.94-0.89 (m, 12H). 
 
 
 
SF(EG)4-epoxy (26) 
SF(EG)4OH (0.22 g, 0.60 mmol) was dissolved in 2 mL dry DMF and cooled to 0 ºC for 
5 min. To the reaction mixture was added NaH (60% dispersion in mineral oil) (0.08 g, 
0.66 mmol) at 0 °C and the reaction was further stirred for one hour. Epibromohydrin 
(0.10 g, 0.66 mmol) was added and the mixture was stirred at rt overnight. Reaction 
mixture was concentrated in vacuo and then dissolved in Et2O (10 mL). Organic layer 
was washed with water (10 mL x 3), brine and dried over Na2SO4. Organic phase was 
filtered and concentrated in vacuo. The reaction mixture was purified by column 
chromatography (40 % EtOAc/ Hexane) to afford 26 (0.13 g, 45%). 1H NMR (400 MHz, 
CDCl3) δ 3.73 (dd, 1H), 3.70-3.63 (m, 13H), 3.60-3.53(m, 1H), 3.51-3.38(m, 3H), 3.21-
3.12 (m, 1H), 2.84-2.77(m, 1H), 2.65-2.60 (m, 1H), 1.64-1.08 (m, 19H), 0.94-0.89 (m, 
12H). 
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SF(EG)5-epoxy (27) 
SF(EG)5OH (0.17 g, 0.40 mmol) was dissolved in 1 mL dry DMF and cooled to 0 ºC for 
5 min. To the reaction mixture was added NaH (60% dispersion in mineral oil) (0.05 g, 
0.44 mmol) at 0 °C and the reaction was further stirred for one hour. Epibromohydrin 
(0.07 g, 0.44 mmol) was added and the mixture was stirred at rt overnight. Reaction 
mixture was concentrated in vacuo and then dissolved in Et2O (5 mL). Organic layer was 
washed with water (10 mL x 3), brine and dried over Na2SO4. Organic phase was filtered 
and concentrated in vacuo. The reaction mixture was purified by column chromatography 
(25 % EtOAc/ Hexane) to afford 27 (0.06 g, 47%). 1H NMR (400 MHz, CDCl3) δ 3.73 
(dd, 1H), 3.70-3.63 (m, 17H), 3.60-3.53(m, 1H), 3.51-3.38(m, 3H), 3.21-3.12 (m, 1H), 
2.84-2.77(m, 1H), 2.65-2.60 (m, 1H), 1.64-1.08 (m, 19H), 0.94-0.89 (m, 12H). 
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1H NMR spectra 
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(not pure) 
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HRMS Spectra 
 
 
HRMS (ESI+): Cacld. for M+: 937.476737, found: 937.476395 
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HRMS (ESI+): Cacld. for M+: 643.402784, found: 643.402634 
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